

# John Trojanowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6816703/publications.pdf>

Version: 2024-02-01

1,007  
papers

183,925  
citations

26

196  
h-index

64

382  
g-index

1086  
all docs

1086  
docs citations

1086  
times ranked

81750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease. <i>Brain</i> , 2022, 145, 879-886.	3.7	17
2	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.4	56
3	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.4	17
4	Genome-wide association study and functional validation implicates JADE1 in tauopathy. <i>Acta Neuropathologica</i> , 2022, 143, 33-53.	3.9	19
5	Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology. <i>NeuroImage: Clinical</i> , 2022, 33, 102913.	1.4	17
6	Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. <i>Cell</i> , 2022, 185, 712-728.e14.	13.5	114
7	Signature laminar distributions of pathology in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 143, 363-382.	3.9	12
8	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	5.8	34
9	Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization. <i>Acta Neuropathologica Communications</i> , 2022, 10, 30.	2.4	8
10	Divergent Histopathological Networks of Frontotemporal Degeneration Proteinopathy Subtypes. <i>Journal of Neuroscience</i> , 2022, 42, 3868-3877.	1.7	4
11	TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss. <i>Acta Neuropathologica Communications</i> , 2022, 10, 33.	2.4	16
12	Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue. <i>Nature Biotechnology</i> , 2022, 40, 1082-1092.	9.4	52
13	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	4.4	7
14	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology. <i>Neurobiology of Aging</i> , 2022, 113, 95-107.	1.5	5
15	Validation of Plasma Amyloid- $\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.5	89
16	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	3.9	29
17	Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change. <i>Acta Neuropathologica Communications</i> , 2022, 10, 50.	2.4	13
18	Lateralized <i>ante mortem</i> and <i>post mortem</i> pathology in a case of Lewy body disease with corticobasal syndrome. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12294.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 75.	2.4	3
20	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
21	Plasma <i>MIA</i> , <i>CRP</i> , and Albumin Predict Cognitive Decline in Parkinson's Disease. <i>Annals of Neurology</i> , 2022, 92, 255-269.	2.8	7
22	Quantitative detection of $\alpha$ -Synuclein and Tau oligomers and other aggregates by digital single particle counting. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	13
23	Genetic prediction of impulse control disorders in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 936-949.	1.7	15
24	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE- $\epsilon$ 4 in female patients with Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 616-634.	5.3	11
25	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, 822-830.	0.4	27
26	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	4.5	144
27	High-Contrast <i>In Vivo</i> Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. <i>Neuron</i> , 2021, 109, 42-58.e8.	3.8	157
28	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
29	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 102-111.	0.9	35
30	PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding. <i>Journal of Biological Chemistry</i> , 2021, 296, 100636.	1.6	21
31	<i>In vitro</i> amplification of pathogenic tau conserves disease-specific bioactive characteristics. <i>Acta Neuropathologica</i> , 2021, 141, 193-215.	3.9	30
32	Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5- <i>a</i> ]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1073-1102.	2.9	17
33	$\alpha$ -Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in <i>BAC</i> SNCA Mice. <i>Movement Disorders</i> , 2021, 36, 2036-2047.	2.2	34
34	Detection of $\beta$ -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	1.5	51
35	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. <i>Neurology</i> , 2021, 96, e1755-e1760.	1.5	1
36	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 30.	2.4	22

#	ARTICLE	IF	CITATIONS
37	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
38	Collaborative Neuropathology Network Characterizing Outcomes of TBI (CONNECT-TBI). <i>Acta Neuropathologica Communications</i> , 2021, 9, 32.	2.4	13
39	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
40	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	1.5	5
41	Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns <i>in vitro</i> and <i>in vivo</i> . <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1033-1049.	1.8	25
42	Tau immunotherapy is associated with glial responses in FTLD-tau. <i>Acta Neuropathologica</i> , 2021, 142, 243-257.	3.9	22
43	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	2.8	30
44	Poly (ADP-ribose) Interacts With Phosphorylated $\pm$ -Synuclein in Post Mortem PD Samples. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704041.	1.7	14
45	Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. <i>Science Advances</i> , 2021, 7, .	4.7	30
46	Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 434-450.	1.8	13
47	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , 2021, 142, 629-642.	3.9	15
48	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. <i>Brain</i> , 2021, 144, 2784-2797.	3.7	38
49	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. <i>Acta Neuropathologica Communications</i> , 2021, 9, 134.	2.4	32
50	Disease-, region- and cell type specific diversity of $\pm$ -synuclein carboxy terminal truncations in synucleinopathies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 146.	2.4	10
51	Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. <i>Acta Neuropathologica Communications</i> , 2021, 9, 140.	2.4	25
52	LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1187-1196.	1.5	5
53	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 2945-2950.	2.2	63
54	Effects of microglial depletion and TREM2 deficiency on $A\beta$ plaque burden and neuritic plaque tau pathology in 5XFAD mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 150.	2.4	19

#	ARTICLE	IF	CITATIONS
55	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	3.9	107
56	The development and convergence of co-pathologies in Alzheimer's disease. <i>Brain</i> , 2021, 144, 953-962.	3.7	76
57	Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor. <i>Brain Communications</i> , 2021, 3, fcb011.	1.5	41
58	Î±-Synuclein modulates tau spreading in mouse brains. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	49
59	Cognitive Profile and Markers of Alzheimer Disease's Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021, 96, e1855-e1864.	1.5	28
60	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 173.	2.4	14
61	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e12595.	3.3	13
62	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021, 11, 105-116.	0.8	5
63	Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. <i>Acta Neuropathologica Communications</i> , 2021, 9, 188.	2.4	29
64	Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau. <i>Acta Neuropathologica Communications</i> , 2021, 9, 184.	2.4	2
65	AD-linked R47H- <i>TREM2</i> mutation induces disease-enhancing microglial states via AKT hyperactivation. <i>Science Translational Medicine</i> , 2021, 13, eabe3947.	5.8	55
66	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI's updates and global perspectives. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12226.	1.8	23
67	Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimer's disease co-pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
68	CSF and blood plasma mass spectrometry measures of AÎ², tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
69	Cerebrospinal fluid neurogranin in non-amnestic and amnestic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
70	Unfolding the medial temporal lobe to characterize neurodegeneration due to Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
71	Calsyneninâ€1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
72	Application of histopathologically derived 3D tau burden map as in vivo region of interest for biomarker analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
73	A novel antibody-free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
74	Regional distribution of tau pathology in subfields of hippocampus among phenotypic variants of AD and FTLD-tau.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052392.	0.4	0
75	Mapping tau burden and neuronal loss in MAPT-associated frontotemporal lobar degeneration.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054141.	0.4	0
76	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
77	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
78	Characterization of hippocampal subfields using ex vivo MRI and histology data: Lessons for in vivo segmentation. <i>Hippocampus</i> , 2020, 30, 545-564.	0.9	31
79	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
80	Transmission of tauopathy strains is independent of their isoform composition. <i>Nature Communications</i> , 2020, 11, 7.	5.8	121
81	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological $\beta$ -Synuclein Insult. <i>Neuron</i> , 2020, 105, 822-836.e7.	3.8	89
82	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 183-193.	0.6	10
83	Amyloid-Beta ( $A\beta$ ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with $A\beta$ Pathology. <i>Neuron</i> , 2020, 105, 260-275.e6.	3.8	141
84	Characterization of novel conformation-selective $\beta$ -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
85	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.4	27
86	An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's disease. <i>Nature Genetics</i> , 2020, 52, 1024-1035.	9.4	191
87	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1141-1146.	0.9	24
88	Characterization of tau binding by gosuranemab. <i>Neurobiology of Disease</i> , 2020, 146, 105120.	2.1	36
89	Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020, 96, 137-147.	1.5	14
90	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33

#	ARTICLE	IF	CITATIONS
91	Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. <i>Acta Neuropathologica</i> , 2020, 140, 831-849.	3.9	37
92	ATN status in amnesic and non-amnesic Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain</i> , 2020, 143, 2295-2311.	3.7	24
93	Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression. <i>Cell Reports</i> , 2020, 33, 108398.	2.9	57
94	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. <i>Cell Reports Medicine</i> , 2020, 1, 100138.	3.3	102
95	Defining and predicting transdiagnostic categories of neurodegenerative disease. <i>Nature Biomedical Engineering</i> , 2020, 4, 787-800.	11.6	22
96	Association of CSF A $\beta$ <sub>2</sub> , amyloid PET, and cognition in cognitively unimpaired elderly adults. <i>Neurology</i> , 2020, 95, e2075-e2085.	1.5	31
97	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020, 140, 449-461.	3.9	7
98	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1643-1648.	1.5	7
99	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. <i>Alzheimer's and Dementia</i> , 2020, 16, 1234-1247.	0.4	15
100	Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. <i>EMBO Molecular Medicine</i> , 2020, 12, e12308.	3.3	73
101	An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. <i>Nature Communications</i> , 2020, 11, 5522.	5.8	56
102	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	1.7	20
103	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	1.7	23
104	Correction of microtubule defects within A $\beta$ <sub>2</sub> plaque-associated dystrophic axons results in lowered A $\beta$ <sub>2</sub> release and plaque deposition. <i>Alzheimer's and Dementia</i> , 2020, 16, 1345-1357.	0.4	11
105	Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1397-1416.	1.2	12
106	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. <i>Acta Neuropathologica</i> , 2020, 140, 675-693.	3.9	15
107	Normalization of CSF pTau measurement by A $\beta$ <sub>40</sub> improves its performance as a biomarker of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 97.	3.0	31
108	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. <i>Brain</i> , 2020, 143, 2844-2857.	3.7	44

#	ARTICLE	IF	CITATIONS
109	Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2020, 79, 941-949.	0.9	6
110	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 64.	4.4	19
111	Cell-to-Cell Transmission of Tau and $\beta$ -Synuclein. <i>Trends in Molecular Medicine</i> , 2020, 26, 936-952.	3.5	91
112	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	3.9	210
113	Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease. <i>Brain</i> , 2020, 143, 1572-1587.	3.7	50
114	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	2.8	55
115	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of $A\beta_{42}$ and Its Protein Aggregates. <i>Molecular Neurobiology</i> , 2020, 57, 3803-3813.	1.9	49
116	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020, 35, 1618-1625.	2.2	31
117	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	4.9	330
118	Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. <i>Npj Vaccines</i> , 2020, 5, 28.	2.9	15
119	Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex. <i>Acta Neuropathologica</i> , 2020, 140, 591-593.	3.9	4
120	Sex and APOE $\epsilon$ 4 genotype modify the Alzheimer's disease serum metabolome. <i>Nature Communications</i> , 2020, 11, 1148.	5.8	115
121	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
122	Synthesis and characterization of high affinity fluorogenic $\beta$ -synuclein probes. <i>Chemical Communications</i> , 2020, 56, 3567-3570.	2.2	24
123	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNI/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020, 66, 587-597.	1.5	15
124	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. <i>Journal of Biological Chemistry</i> , 2020, 295, 4001-4013.	1.6	10
125	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. <i>Nature Communications</i> , 2020, 11, 667.	5.8	246
126	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. <i>Nature Medicine</i> , 2020, 26, 769-780.	15.2	547



#	ARTICLE	IF	CITATIONS
127	Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 80.	1.7	139
128	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 843-852.	0.4	43
129	Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	73
130	Astroglial tau pathology alone preferentially concentrates at sulcal depths in chronic traumatic encephalopathy neuropathologic change. <i>Brain Communications</i> , 2020, 2, fcaa210.	1.5	19
131	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 296-304.	0.9	35
132	Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 1912-1930.	3.9	268
133	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
134	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	2.8	88
135	Cerebrospinal Fluid Total and Phosphorylated $\beta$ -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019, 56, 3476-3483.	1.9	26
136	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 440-445.	0.8	15
137	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	3.7	11
138	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. <i>Acta Neuropathologica</i> , 2019, 138, 795-811.	3.9	50
139	Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019, 142, 2581-2589.	3.7	65
140	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 682.	1.4	13
141	Spread of $\beta$ -synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. <i>Nature Neuroscience</i> , 2019, 22, 1248-1257.	7.1	187
142	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples. <i>Acta Neuropathologica</i> , 2019, 138, 613-630.	3.9	68
143	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. <i>JAMA Network Open</i> , 2019, 2, e197978.	2.8	142
144	Longitudinal analyses of cerebrospinal fluid $\beta$ -Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1354-1364.	2.2	89

#	ARTICLE	IF	CITATIONS
145	Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. <i>Journal of Biological Chemistry</i> , 2019, 294, 12754-12765.	1.6	114
146	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from $\alpha$ -Synucleinopathies. <i>Radiology</i> , 2019, 293, 646-653.	3.6	20
147	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. <i>Brain</i> , 2019, 142, 3565-3579.	3.7	80
148	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , 2019, 16, e1002931.	3.9	42
149	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	192
150	Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein ( $\alpha$ -Syn) Pathology in Synthetic $\alpha$ -Syn Fibril-Induced Mouse Models of Synucleinopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 877-890.	0.9	46
151	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14
152	Genetic predictors of survival in behavioral variant frontotemporal degeneration. <i>Neurology</i> , 2019, 93, e1707-e1714.	1.5	11
153	Chronic traumatic encephalopathy "confusion and controversies. <i>Nature Reviews Neurology</i> , 2019, 15, 179-183.	4.9	111
154	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
155	$\alpha$ -Synuclein pathology in Parkinson's disease and related $\alpha$ -synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	1.0	177
156	APOE Effect on Amyloid- $\beta$ PET Spatial Distribution, Deposition Rate, and Cut-Points. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 783-793.	1.2	15
157	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. <i>Acta Neuropathologica</i> , 2019, 138, 389-399.	3.9	108
158	Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 65.	2.4	20
159	Longitudinal progression of grey matter atrophy in non-amnesic Alzheimer's disease. <i>Brain</i> , 2019, 142, 1701-1722.	3.7	37
160	$\alpha$ -Synuclein ( $\alpha$ -Syn) Preformed Fibrils Induce Endogenous $\alpha$ -Syn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons. <i>Journal of Neuroscience</i> , 2019, 39, 5080-5094.	1.7	76
161	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
162	Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). <i>Acta Neuropathologica Communications</i> , 2019, 7, 34.	2.4	27

#	ARTICLE	IF	CITATIONS
163	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.4	72
164	LRRK2 inhibition does not impart protection from $\beta$ -synuclein pathology and neuron death in non-transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 28.	2.4	39
165	Divergent patterns of TDP $\epsilon$ 43 and tau pathologies in primary progressive aphasia. <i>Annals of Neurology</i> , 2019, 85, 630-643.	2.8	40
166	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 263-276.	1.2	13
167	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019, 85, 801-811.	2.8	52
168	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
169	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	2.8	118
170	Genome-wide analyses as part of the international FTL-D-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTL. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
171	Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. <i>Methods in Molecular Biology</i> , 2019, 1948, 45-57.	0.4	21
172	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
173	Primum non nocere: a call for balance when reporting on CTE. <i>Lancet Neurology</i> , The, 2019, 18, 231-233.	4.9	48
174	Transmission of $\beta$ -synuclein seeds in neurodegenerative disease: recent developments. <i>Laboratory Investigation</i> , 2019, 99, 971-981.	1.7	74
175	Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 183.	2.4	101
176	Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges?. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 183-201.	0.9	12
177	IC $\epsilon$ 43: CONTRIBUTION OF TAU, TDP $\epsilon$ 43, $A\beta$ AND $\beta$ -SYNUCLEIN TO MEDIAL TEMPORAL LOBE ATROPHY. <i>Alzheimer's and Dementia</i> , 2019, 15, P46.	0.4	0
178	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	30
179	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys $A\beta$ (1 $\epsilon$ 42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , 2019, 9, 19024.	1.6	123
180	Mechanisms of Cell-to-Cell Transmission of Pathological Tau. <i>JAMA Neurology</i> , 2019, 76, 101.	4.5	162

#	ARTICLE	IF	CITATIONS
181	Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. <i>Neurobiology of Disease</i> , 2019, 124, 133-140.	2.1	28
182	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid- $\beta$ pathology. <i>Molecular Neurodegeneration</i> , 2019, 14, 1.	4.4	253
183	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
184	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 106-152.	0.4	302
185	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
186	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease: An emerging role for gut microbiome. <i>Alzheimer's and Dementia</i> , 2019, 15, 76-92.	0.4	396
187	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. <i>Alzheimer's and Dementia</i> , 2019, 15, 232-244.	0.4	198
188	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. <i>Nature Medicine</i> , 2019, 25, 152-164.	15.2	111
189	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	4.5	161
190	Elevated YKL-40 and low sAPP $\beta$ :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTL. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	0.9	17
191	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2019, 73, 190-199.	1.5	31
192	Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. <i>Nature Neuroscience</i> , 2018, 21, 329-340.	7.1	220
193	CSF tau and $\beta$ -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018, 90, e1038-e1046.	1.5	68
194	CSF biomarkers of Alzheimer's disease concord with amyloid- $\beta$ PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481.	0.4	468
195	Measurements of autoantibodies to $\alpha$ -synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 489-503.	2.1	47
196	Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease. <i>Nature Neuroscience</i> , 2018, 21, 497-505.	7.1	236
197	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136
198	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1365-1375.	1.8	73

#	ARTICLE	IF	CITATIONS
199	Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 216-228.	0.9	69
200	A Longitudinal Study of Total and Phosphorylated $\beta$ -Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1541-1553.	1.2	29
201	Is multiple system atrophy an infectious disease?. <i>Annals of Neurology</i> , 2018, 83, 10-12.	2.8	16
202	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. <i>Brain</i> , 2018, 141, 288-301.	3.7	56
203	Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2180-2183.	1.0	21
204	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
205	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
206	Cerebrospinal fluid $\beta$ -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
207	Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4252-4257.	3.3	136
208	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
209	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> , 2018, 75, 738.	4.5	54
210	Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases. <i>Brain Pathology</i> , 2018, 28, 274-283.	2.1	12
211	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
212	<i>APOE</i> , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
213	Neocortical origin and progression of gray matter atrophy in nonamnesic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 75-87.	1.5	61
214	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
215	Spread of aggregates after olfactory bulb injection of $\beta$ -synuclein fibrils is associated with early neuronal loss and is reduced long term. <i>Acta Neuropathologica</i> , 2018, 135, 65-83.	3.9	154
216	P1-398: PARIETAL LOBE CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH LOWER CEREBROSPINAL FLUID BETA AMYLOID <sub>1-42</sub> IN PATIENTS WITH SPORADIC AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P454.	0.4	0

#	ARTICLE	IF	CITATIONS
217	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P327.	0.4	0
218	P1â€281: NONLINEAR Nâ€SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. <i>Alzheimer's and Dementia</i> , 2018, 14, P390.	0.4	1
219	P1â€143: MULTIVARIATE GENOMEâ€WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION. <i>Alzheimer's and Dementia</i> , 2018, 14, P330.	0.4	0
220	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P997.	0.4	0
221	P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P275.	0.4	0
222	O2â€14â€01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. <i>Alzheimer's and Dementia</i> , 2018, 14, P656.	0.4	0
223	P1â€255: ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LCâ€MSâ€MS REFERENCE METHOD. <i>Alzheimer's and Dementia</i> , 2018, 14, P378.	0.4	0
224	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. <i>Molecular Neurodegeneration</i> , 2018, 13, 59.	4.4	27
225	P1â€419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P465.	0.4	0
226	<sc>CSF</sc> progranulin increases in the course of Alzheimer's disease and is associated with <sc>TREM</sc> 2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	64
227	LRP10 in Î±-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1033-1034.	4.9	11
228	The Parkinson's progression markers initiative (PPMI) â€ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
229	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-Î²1-42 and Hypertension. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1095-1104.	1.2	21
230	LRP10 in Î±-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	4.9	11
231	Derivation of cutoffs for the Elecsys <sup>â€</sup> amyloid Î²² (1â€42) assay in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 698-705.	1.2	50
232	Current state of Alzheimerâ€™s fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
233	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
234	Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. <i>Nature Communications</i> , 2018, 9, 4220.	5.8	176

#	ARTICLE	IF	CITATIONS
235	Converging Patterns of $\beta$ -Synuclein Pathology in Multiple System Atrophy. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2018, 77, 1005-1016.	0.9	26
236	Amyloid- $\beta$ plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. <i>Nature Medicine</i> , 2018, 24, 29-38.	15.2	433
237	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	3.9	87
238	Sequential stages and distribution patterns of aging-related tau astroglial pathology (ARTAG) in the human brain. <i>Acta Neuropathologica Communications</i> , 2018, 6, 50.	2.4	77
239	Cerebrospinal fluid tau, $A\beta$ , and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1159-1170.	0.4	96
240	Cellular milieu imparts distinct pathological $\beta$ -synuclein strains in $\beta$ -synucleinopathies. <i>Nature</i> , 2018, 557, 558-563.	13.7	457
241	LRRK2 activity does not dramatically alter $\beta$ -synuclein pathology in primary neurons. <i>Acta Neuropathologica Communications</i> , 2018, 6, 45.	2.4	34
242	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. <i>Journal of Experimental Medicine</i> , 2018, 215, 2355-2377.	4.2	173
243	Alzheimer's genetic risk is reduced in primary age-related tauopathy: a potential model of resistance?. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 927-934.	1.7	14
244	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
245	The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologicals in Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0193707.	1.1	30
246	Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. <i>Acta Neuropathologica</i> , 2018, 136, 377-388.	3.9	112
247	Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. <i>Brain</i> , 2017, 140, aww319.	3.7	114
248	Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017, 13, 106-115.	1.4	48
249	Expansion of the classification of FTLT-DTP: distinct pathology associated with rapidly progressive frontotemporal degeneration. <i>Acta Neuropathologica</i> , 2017, 134, 65-78.	3.9	163
250	Typical and atypical pathology in primary progressive aphasia variants. <i>Annals of Neurology</i> , 2017, 81, 430-443.	2.8	288
251	Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. <i>Alzheimer's and Dementia</i> , 2017, 13, 770-777.	0.4	20
252	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , 2017, 133, 839-856.	3.9	199

#	ARTICLE	IF	CITATIONS
253	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	1.5	37
254	Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. <i>Neurology</i> , 2017, 88, 2276-2284.	1.5	114
255	Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. <i>Journal of Neuroscience</i> , 2017, 37, 5870-5884.	1.7	30
256	Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2017, 82, 139-146.	2.8	88
257	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
258	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1245-1254.	1.2	54
259	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5120-5145.	2.9	40
260	Multisite Assessment of Aging-Related Tau Astroglipathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	0.9	38
261	Evaluating the Patterns of Aging-Related Tau Astroglipathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 270-288.	0.9	98
262	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, e1-e85.	0.4	213
263	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinson's Disease</i> , 2017, 7, 385-395.	1.5	21
264	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	179
265	Metabolic network failures in Alzheimer's disease: A biochemical roadmap. <i>Alzheimer's and Dementia</i> , 2017, 13, 965-984.	0.4	362
266	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	4.9	394
267	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. <i>Neurobiology of Disease</i> , 2017, 105, 328-335.	2.1	74
268	Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. <i>ACS Chemical Neuroscience</i> , 2017, 8, 5-7.	1.7	20
269	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , 2017, 13, 561-571.	0.4	266
270	Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. <i>Acta Neuropathologica</i> , 2017, 133, 955-966.	3.9	60



#	ARTICLE	IF	CITATIONS
271	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	1.5	70
272	GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. <i>Journal of Neuroscience</i> , 2017, 37, 11485-11494.	1.7	28
273	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. <i>Neurology</i> , 2017, 89, 1959-1969.	1.5	121
274	Clinicopathological correlations in behavioural variant frontotemporal dementia. <i>Brain</i> , 2017, 140, 3329-3345.	3.7	226
275	Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain. <i>Journal of Neuroscience</i> , 2017, 37, 11406-11423.	1.7	284
276	Modeling Parkinson's disease pathology by combination of fibril seeds and $\alpha$ -synuclein overexpression in the rat brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8284-E8293.	3.3	161
277	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017, 82, 247-258.	2.8	51
278	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
279	Protein astrogliopathies in human neurodegenerative diseases and aging. <i>Brain Pathology</i> , 2017, 27, 675-690.	2.1	68
280	TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. <i>Current Biology</i> , 2017, 27, 3579-3590.e6.	1.8	63
281	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
282	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , 2017, 140, aww339.	3.7	153
283	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	1.7	40
284	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 864-868.	1.3	32
285	Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults. <i>Neurobiology of Aging</i> , 2017, 58, 102-111.	1.5	15
286	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. <i>BMC Medical Genomics</i> , 2017, 10, 29.	0.7	28
287	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. <i>Neuron</i> , 2017, 95, 297-308.e6.	3.8	171
288	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12

#	ARTICLE	IF	CITATIONS
289	Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 315-329.	1.8	44
290	[P4 <sup>155</sup> ]: DERIVING A CUTOFF FOR THE ELECSYS <sup>®</sup> $\beta$ -AMYLOID (1 <sup>42</sup> ) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER'S DISEASE (AD). <i>Alzheimer's and Dementia</i> , 2017, 13, P1317.	0.4	2
291	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 89.	3.0	129
292	Regional brain amyloid- $\beta$ accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017, 12, e0177924.	1.1	33
293	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. <i>Acta Neuropathologica Communications</i> , 2017, 5, 68.	2.4	34
294	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
295	Deep clinical and neuropathological phenotyping of <sc>P</sc>ick disease. <i>Annals of Neurology</i> , 2016, 79, 272-287.	2.8	146
296	Plasma <sc>EGF</sc> and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 346-355.	1.7	41
297	Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 99-107.	1.2	23
298	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. <i>Scientific Reports</i> , 2016, 6, 34904.	1.6	67
299	â€œNew Old Pathologiesâ€ AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 482-498.	0.9	130
300	Multisite assessment of NIAâ€AA guidelines for the neuropathologic evaluation of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 164-169.	0.4	82
301	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	1.5	174
302	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 21-26.	1.1	42
303	Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. <i>JAMA Neurology</i> , 2016, 73, 733.	4.5	131
304	Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. <i>Cell Reports</i> , 2016, 16, 3373-3387.	2.9	141
305	TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. <i>Brain</i> , 2016, 139, 2983-2993.	3.7	298
306	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.5	371

#	ARTICLE	IF	CITATIONS
307	Cognitive reserve in frontotemporal degeneration. <i>Neurology</i> , 2016, 87, 1813-1819.	1.5	40
308	Widespread transneuronal propagation of $\alpha$ -synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. <i>Journal of Experimental Medicine</i> , 2016, 213, 1759-1778.	4.2	309
309	Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 399-403.	1.7	56
310	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016, 31, 126-134.	2.2	20
311	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	4.5	185
312	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. <i>Neurology</i> , 2016, 87, 1227-1234.	1.5	25
313	Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy. <i>Journal of Neuroscience</i> , 2016, 36, 7707-7717.	1.7	62
314	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	9.4	494
315	Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 2635-2654.	4.2	310
316	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. <i>BMC Medical Genomics</i> , 2016, 9, 30.	0.7	20
317	Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. <i>Alzheimer's and Dementia</i> , 2016, 12, 1051-1065.	0.4	91
318	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 106.	2.4	45
319	Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 935-937.	3.9	81
320	Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice. <i>Acta Neuropathologica Communications</i> , 2016, 4, 105.	2.4	16
321	Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. <i>Neuron</i> , 2016, 91, 41-55.	3.8	75
322	Amyloid- $\beta$ Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 367-375.	0.8	28
323	Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 54-66.	1.3	43
324	Ageing-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	3.9	380

#	ARTICLE	IF	CITATIONS
325	Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimers Disease and Related Tauopathies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 357, 432-450.	1.3	58
326	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <sc>P</sc>arkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
327	CSF biomarkers associated with disease heterogeneity in early Parkinsonâ€™s disease: the Parkinsonâ€™s Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
328	Pathological Î±-synuclein distribution in subjects with coincident Alzheimerâ€™s and Lewy body pathology. <i>Acta Neuropathologica</i> , 2016, 131, 393-409.	3.9	123
329	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , 2016, 73, 60.	4.5	354
330	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	4.1	260
331	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. <i>PLoS ONE</i> , 2016, 11, e0147319.	1.1	25
332	CSF betaâ€œamyloid 1â€œ42 â€œ what are we measuring in Alzheimer's disease?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 131-139.	1.7	34
333	Validation of the Erlangen Score Algorithm for the Prediction of the Development ofâ€œDementia due to Alzheimerâ€™s Disease inâ€œPre-Dementia Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 433-441.	1.2	41
334	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inâ€œAlzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 987-994.	1.2	67
335	Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His. <i>Acta Neuropathologica Communications</i> , 2015, 3, 42.	2.4	14
336	Neuropathology and <sc>C</sc>ellular <sc>P</sc>athogenesis of <sc>S</sc>pinocerebellar <sc>A</sc>taxia <sc>T</sc>ype 12. <i>Movement Disorders</i> , 2015, 30, 1813-1824.	2.2	32
337	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i>-Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	4.5	272
338	Rarity of the Alzheimer Diseaseâ€œProtective <i>APP</i>A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
339	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. <i>Acta Neuropathologica</i> , 2015, 130, 363-372.	3.9	65
340	Guidelines for the standardization of preanalytic variables for bloodâ€œbased biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
341	Clinicopathological Study of Patients With <i>C9ORF72</i>-Associated Frontotemporal Dementia Presenting With Delusions. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 99-107.	1.2	41
342	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. <i>Acta Neuropathologica</i> , 2015, 129, 469-491.	3.9	218

#	ARTICLE	IF	CITATIONS
343	Independent information from cerebrospinal fluid amyloid- $\beta^2$ and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015, 138, 772-783.	3.7	200
344	An acetylation switch controls TDP-43 function and aggregation propensity. <i>Nature Communications</i> , 2015, 6, 5845.	5.8	231
345	<i>PARK10</i> is a major locus for sporadic neuropathologically confirmed Parkinson disease. <i>Neurology</i> , 2015, 84, 972-980.	1.5	48
346	Cognitive profile of <i>LRRK2</i> -related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	2.2	64
347	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. <i>Science</i> , 2015, 347, 1436-1441.	6.0	823
348	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <i>Nature Reviews Neuroscience</i> , 2015, 16, 109-120.	4.9	611
349	Building a roadmap for developing combination therapies for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 327-333.	1.4	54
350	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015, 11, e1-120.	0.4	261
351	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.4	181
352	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.4	79
353	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
354	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015, 6, 7247.	5.8	170
355	The <i>TMEM106B</i> locus and TDP-43 pathology in older persons without FTL. <i>Neurology</i> , 2015, 84, 927-934.	1.5	71
356	Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. <i>Acta Neuropathologica</i> , 2015, 130, 643-660.	3.9	215
357	Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC afferent and efferent connections. <i>Acta Neuropathologica</i> , 2015, 130, 349-362.	3.9	174
358	Memory, executive, and multidomain subtle cognitive impairment. <i>Neurology</i> , 2015, 85, 144-153.	1.5	42
359	Intrastriatal injection of pre-formed mouse $\alpha$ -synuclein fibrils into rats triggers $\alpha$ -synuclein pathology and bilateral nigrostriatal degeneration. <i>Neurobiology of Disease</i> , 2015, 82, 185-199.	2.1	285
360	Variants associated with Gaucher disease in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 417-426.	1.7	90

#	ARTICLE	IF	CITATIONS
361	Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. <i>Acta Neuropathologica</i> , 2015, 129, 221-237.	3.9	211
362	<i>APOE</i> effect on Alzheimer's disease biomarkers in older adults with significant memory concern. <i>Alzheimer's and Dementia</i> , 2015, 11, 1417-1429.	0.4	157
363	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 154-166.	0.7	29
364	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 $\beta$ -Amyloid Measures Across the Spectrum of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 571.	4.5	87
365	Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTL-DTP and ALSC9orf72 Expansion Cases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 380-387.	0.9	28
366	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	3.9	139
367	Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4980-4982.	1.0	31
368	The transitional association between $\beta$ -amyloid pathology and regional brain atrophy. <i>Alzheimer's and Dementia</i> , 2015, 11, 1171-1179.	0.4	37
369	T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 598-604.	1.4	29
370	High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. <i>Acta Neuropathologica Communications</i> , 2015, 3, 33.	2.4	18
371	Role of brain infarcts in behavioral variant frontotemporal dementia. <i>Neurobiology of Aging</i> , 2015, 36, 2861-2868.	1.5	14
372	An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. <i>Human Molecular Genetics</i> , 2015, 24, 7241-7254.	1.4	39
373	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.5	197
374	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3373-3385.	3.7	200
375	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 992-995.	1.1	29
376	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 273-282.	1.5	30
377	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , 2015, 30, 805-812.	2.2	37
378	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. <i>Neurobiology of Disease</i> , 2015, 73, 83-95.	2.1	168

#	ARTICLE	IF	CITATIONS
379	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. <i>PLoS ONE</i> , 2015, 10, e0125614.	1.1	124
380	Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin. <i>PLoS ONE</i> , 2015, 10, e0141836.	1.1	40
381	Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies. <i>Korean Journal of Physiology and Pharmacology</i> , 2014, 18, 447.	0.6	13
382	Astrocytic TDP-43 Pathology in Alexander Disease. <i>Journal of Neuroscience</i> , 2014, 34, 6448-6458.	1.7	64
383	Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497. <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 355-360.	2.4	11
384	Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 466-472.	1.1	2
385	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. <i>PLoS Genetics</i> , 2014, 10, e1004606.	1.5	305
386	P3-018: INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE. , 2014, 10, P633-P633.		0
387	Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. <i>Brain</i> , 2014, 137, 2578-2587.	3.7	132
388	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. <i>Neurology</i> , 2014, 83, 502-509.	1.5	26
389	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014, 29, 1258-1264.	2.2	76
390	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543.	1.7	96
391	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. <i>Acta Neuropathologica Communications</i> , 2014, 2, 26.	2.4	77
392	A Novel <i>GRN</i> Mutation ( <i>GRN</i> c.708+6_+9delTGAC) in Frontotemporal Lobar Degeneration With TDP-43 Positive Inclusions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 467-473.	0.9	7
393	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 442.	4.5	74
394	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	4.5	166
395	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86
396	Emerging $\beta$ -Amyloid Pathology and Accelerated Cortical Atrophy. <i>JAMA Neurology</i> , 2014, 71, 725.	4.5	51

#	ARTICLE	IF	CITATIONS
397	<i>APOE</i>, <i>MAPT</i>, and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	4.5	172
398	The Growth and Impact of Alzheimer Disease Centers as Measured by Social Network Analysis. <i>JAMA Neurology</i> , 2014, 71, 412.	4.5	22
399	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.4	250
400	CSF Apo-E levels associate with cognitive decline and MRI changes. <i>Acta Neuropathologica</i> , 2014, 127, 621-632.	3.9	60
401	The power of neuroimaging biomarkers for screening frontotemporal dementia. <i>Human Brain Mapping</i> , 2014, 35, 4827-4840.	1.9	48
402	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	3.9	123
403	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). <i>Acta Neuropathologica</i> , 2014, 127, 423-439.	3.9	237
404	The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 372-378.	0.9	45
405	Therapeutic modulation of eIF2 $\gamma$ phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. <i>Nature Genetics</i> , 2014, 46, 152-160.	9.4	321
406	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. <i>Acta Neuropathologica</i> , 2014, 128, 679-689.	3.9	158
407	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	3.9	1,060
408	Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4171-4175.	1.0	9
409	$\beta$ -Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded $\beta$ -Synuclein and Neurodegeneration. <i>Cell Reports</i> , 2014, 7, 2054-2065.	2.9	287
410	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. <i>Drug and Alcohol Dependence</i> , 2014, 142, 262-268.	1.6	25
411	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. <i>Acta Neuropathologica</i> , 2014, 128, 423-437.	3.9	203
412	Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. <i>Acta Neuropathologica Communications</i> , 2014, 2, 33.	2.4	25
413	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
414	Association of plasma and cortical amyloid beta is modulated by <i>APOE</i> $\epsilon$ 4 status. <i>Alzheimer's and Dementia</i> , 2014, 10, e9-e18.	0.4	43



#	ARTICLE	IF	CITATIONS
415	Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer's Disease and Related Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6116-6127.	2.9	84
416	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A <sub>2</sub> )-Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1015-1020.	1.3	6
417	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.4	167
418	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5040-5049.	1.4	87
419	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2014, 35, 1473-1482.	1.5	43
420	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 461-472.	1.4	45
421	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2014, 35, 614-622.	1.5	42
422	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. <i>NeuroImage: Clinical</i> , 2014, 4, 164-173.	1.4	112
423	Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 827-830.	2.2	24
424	A comparison of A $\beta$ <sup>2</sup> amyloid pathology staging systems and correlation with clinical diagnosis. <i>Acta Neuropathologica</i> , 2014, 128, 543-550.	3.9	26
425	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, S226-35.	0.4	51
426	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid- $\beta$ <sup>242</sup> in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 441-451.	1.2	94
427	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 36.	3.0	26
428	O2-05-06: COMBINING CSF AB42 AND PET FLORBETAPIR TO PREDICT DIAGNOSIS, TAU, ATROPHY, AND COGNITION. , 2014, 10, P174-P174.		1
429	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
430	P4-054: ASSOCIATION OF PLASMA LEPTIN/ADIPONECTIN RATIO IN MEN WITH CSF BIOMARKERS IN THE ADNI-1 COHORT. , 2014, 10, P801-P802.		0
431	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
432	O3-12-05: INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE. , 2014, 10, P234-P234.		0

#	ARTICLE	IF	CITATIONS
433	P2-094: COMPARING THE DIAGNOSTIC ACCURACIES OF CSF A $\beta$ 242 AND PET FLORBETAPIR. , 2014, 10, P505-P505.		0
434	P3-017: ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE. , 2014, 10, P632-P633.		0
435	P4-076: INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF A $\beta$ 1-42. , 2014, 10, P811-P811.		6
436	P4-377: A TOMM40 SNP IN APOE E4 NON-CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA. , 2014, 10, P926-P926.		0
437	P3-189: DIAGNOSTIC EFFECTIVENESS OF QUANTITATIVE [18F]FLUTEMETAMOL PET IMAGING IN SUBJECTS WITH NORMAL PRESSURE HYDROCEPHALUS USING BIOPSY HISTOPATHOLOGY STANDARD OF TRUTH FOR DETECTION OF FIBRILLAR AMYLOID B. , 2014, 10, P699-P699.		0
438	P4-237: WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT. , 2014, 10, P873-P874.		0
439	Parkinson's disease dementia: convergence of $\alpha$ -synuclein, tau and amyloid- $\beta$ pathologies. <i>Nature Reviews Neuroscience</i> , 2013, 14, 626-636.	4.9	673
440	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 886-889.	1.3	33
441	Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without <i>GBA</i> Mutations. <i>JAMA Neurology</i> , 2013, 70, 852.	4.5	115
442	Association of Cerebrospinal Fluid $\beta$ -Amyloid 1-42, T-tau, P-tau <sub>181</sub> , and $\alpha$ -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 1277-87.	4.5	318
443	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. <i>Acta Neuropathologica Communications</i> , 2013, 1, 36.	2.4	32
444	Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. <i>Acta Neuropathologica Communications</i> , 2013, 1, 1-11.	2.4	13
445	CSF $\alpha$ -synuclein improves diagnostic and prognostic performance of CSF tau and A $\beta$ in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 683-697.	3.9	90
446	Inflammation and white matter degeneration persist for years after a single traumatic brain injury. <i>Brain</i> , 2013, 136, 28-42.	3.7	819
447	TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age. <i>JAMA Neurology</i> , 2013, 70, 1418.	4.5	200
448	Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. <i>Nature Reviews Neurology</i> , 2013, 9, 708-714.	4.9	432
449	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. <i>Journal of Comparative Neurology</i> , 2013, 521, 4339-4355.	0.9	47
450	Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?. <i>Acta Neuropathologica</i> , 2013, 126, 625-629.	3.9	5

#	ARTICLE	IF	CITATIONS
451	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. <i>Brain</i> , 2013, 136, 2697-2706.	3.7	609
452	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of $\beta$ -amyloid. <i>Annals of Neurology</i> , 2013, 74, 826-836.	2.8	320
453	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	4.9	3,378
454	Longitudinal change in CSF Tau and $A\beta$ biomarkers for up to 48 months in ADNI. <i>Acta Neuropathologica</i> , 2013, 126, 659-670.	3.9	160
455	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. <i>Acta Neuropathologica Communications</i> , 2013, 1, 65.	2.4	138
456	Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. <i>Neuron</i> , 2013, 79, 1094-1108.	3.8	673
457	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2013, 333, 9-12.	0.3	55
458	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 8.	3.0	113
459	TDP-43 skeins show properties of amyloid in a subset of ALS cases. <i>Acta Neuropathologica</i> , 2013, 125, 121-131.	3.9	95
460	APOE $\epsilon$ 4 Increases Risk for Dementia in Pure Synucleinopathies. <i>JAMA Neurology</i> , 2013, 70, 223.	4.5	302
461	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
462	Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. <i>Brain and Language</i> , 2013, 127, 106-120.	0.8	77
463	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013, 9, 609-614.	0.4	24
464	Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies. <i>American Journal of Pathology</i> , 2013, 183, 344-351.	1.9	104
465	O2-10-01: TDP-43 and mixed pathologies in normal cognition, mild cognitive impairment and dementia. , 2013, 9, P334-P334.		0
466	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
467	Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy. <i>Journal of Neuroscience</i> , 2013, 33, 1024-1037.	1.7	548
468	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. <i>Annals of Neurology</i> , 2013, 74, 119-127.	2.8	116

#	ARTICLE	IF	CITATIONS
469	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. <i>Nature</i> , 2013, 495, 467-473.	13.7	1,249
470	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- $\beta$ 42 and $\beta$ , Proteins as Alzheimer Disease Biomarkers. <i>Clinical Chemistry</i> , 2013, 59, 903-916.	1.5	139
471	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. <i>Neuron</i> , 2013, 78, 256-268.	3.8	344
472	Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone. <i>JAMA Neurology</i> , 2013, 70, 462.	4.5	153
473	Stages of pTDP43 pathology in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2013, 74, 20-38.	2.8	820
474	Distinct $\alpha$ -Synuclein Strains Differentially Promote Tau Inclusions in Neurons. <i>Cell</i> , 2013, 154, 103-117.	13.5	574
475	Patterns of Striatal Degeneration in Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 74-83.	0.6	55
476	Cognitive decline and reduced survival in <i>C9orf72</i> expansion frontotemporal degeneration and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 163-169.	0.9	141
477	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 949-955.	0.9	82
478	Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation. <i>Journal of Biological Chemistry</i> , 2013, 288, 11024-11037.	1.6	128
479	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	4.5	374
480	Frequency and Clinicopathological Characteristics of Presenilin 1 Gly206Ala Mutation in Puerto Rican Hispanics with Dementia. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1089-1095.	1.2	25
481	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. <i>PLoS ONE</i> , 2013, 8, e55531.	1.1	41
482	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 11.	1.7	126
483	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 6.	1.7	79
484	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. <i>PLoS ONE</i> , 2013, 8, e70269.	1.1	50
485	Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. <i>Biochemical Society Transactions</i> , 2012, 40, 661-666.	1.6	39
486	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. <i>Human Molecular Genetics</i> , 2012, 21, 3500-3512.	1.4	198

#	ARTICLE	IF	CITATIONS
487	Intracerebral inoculation of pathological $\alpha$ -synuclein initiates a rapidly progressive neurodegenerative $\alpha$ -synucleinopathy in mice. <i>Journal of Experimental Medicine</i> , 2012, 209, 975-986.	4.2	910
488	Phosphorylated $\alpha$ -Synuclein in Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 121ra20.	5.8	223
489	Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. <i>EMBO Journal</i> , 2012, 31, 1241-1252.	3.5	170
490	Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2012, 21, 2899-2911.	1.4	246
491	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 856-67.	4.9	99
492	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	0.9	1,599
493	Saccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 509.	4.9	97
494	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. <i>Brain</i> , 2012, 135, 3749-3756.	3.7	228
495	<i>TMEM106B</i> , the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways. <i>Journal of Neuroscience</i> , 2012, 32, 11213-11227.	1.7	195
496	Pathological $\alpha$ -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. <i>Science</i> , 2012, 338, 949-953.	6.0	2,024
497	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <i>Neurology</i> , 2012, 79, 897-905.	1.5	208
498	Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1310.	4.9	186
499	Brain-Penetrant Tetrahydronaphthalene Thromboxane A <sub>2</sub> -Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 928-940.	1.7	22
500	Comparison of Cerebrospinal Fluid Levels of Tau and A $\beta$ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. <i>Archives of Neurology</i> , 2012, 69, 1018-25.	4.9	100
501	Primary or secondary prevention for AD: who cares?. <i>Lancet Neurology</i> , The, 2012, 11, 661-662.	4.9	2
502	Neuropathologic substrates of Parkinson disease dementia. <i>Annals of Neurology</i> , 2012, 72, 587-598.	2.8	401
503	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 1-13.	0.4	1,968
504	S501: Microtubule-stabilizing drugs for abrogation and prevention of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P724.	0.4	0

#	ARTICLE	IF	CITATIONS
505	O4â€1â€01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of AÅŸ, tau and Pâ€tau versus 83 proteomic analytes. <i>Alzheimer's and Dementia</i> , 2012, 8, P609.	0.4	0
506	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	1.5	346
507	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1599-1608.	1.5	52
508	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. <i>Brain</i> , 2012, 135, 807-818.	3.7	226
509	Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structureâ€activity relationship leads to selection of candidates with desirable in vivo properties. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4451-4461.	1.4	29
510	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. <i>Journal of Neuroscience</i> , 2012, 32, 3601-3611.	1.7	325
511	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2012, 13, 38-50.	4.9	568
512	Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2012, 7, e39216.	1.1	210
513	Comparison of xMAP and ELISA Assays for Detecting Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 439-445.	1.2	59
514	Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 7392-7402.	1.7	98
515	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <i>Acta Neuropathologica</i> , 2012, 124, 23-35.	3.9	161
516	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. <i>Science Translational Medicine</i> , 2012, 4, 141ra90.	5.8	444
517	TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. <i>Acta Neuropathologica</i> , 2012, 124, 285-291.	3.9	24
518	Pattern of ubiquilin pathology in ALS and FTLN indicates presence of C9ORF72 hexanucleotide expansion. <i>Acta Neuropathologica</i> , 2012, 123, 825-839.	3.9	164
519	Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. <i>Acta Neuropathologica</i> , 2012, 124, 221-230.	3.9	37
520	Longitudinal plasma amyloid beta as a biomarker of Alzheimerâ€™s disease. <i>Journal of Neural Transmission</i> , 2012, 119, 843-850.	1.4	54
521	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. <i>Lancet Neurology</i> , The, 2012, 11, 323-330.	4.9	1,039
522	National Institute on Agingâ€™s Alzheimerâ€™s Association guidelines for the neuropathologic assessment of Alzheimerâ€™s disease: a practical approach. <i>Acta Neuropathologica</i> , 2012, 123, 1-11.	3.9	2,002

#	ARTICLE	IF	CITATIONS
523	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2012, 123, 395-407.	3.9	104
524	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <i>Journal of Clinical Investigation</i> , 2012, 122, 1316-1338.	3.9	1,431
525	A "Two-hit" Hypothesis for Inclusion Formation by Carboxyl-terminal Fragments of TDP-43 Protein Linked to RNA Depletion and Impaired Microtubule-dependent Transport. <i>Journal of Biological Chemistry</i> , 2011, 286, 18845-18855.	1.6	98
526	Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to the Design of Potent Thromboxane (A <sub>2</sub> ) Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6969-6983.	2.9	35
527	The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. <i>Pharmacological Research</i> , 2011, 63, 341-351.	3.1	135
528	Asymmetric bilateral demyelinating optic neuropathy from tacrolimus toxicity. <i>Journal of the Neurological Sciences</i> , 2011, 301, 112-115.	0.3	33
529	Â-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies. <i>Journal of Neuroscience</i> , 2011, 31, 10076-10087.	1.7	105
530	<i>In Vivo</i> Positron Emission Tomographic Imaging of Glial Responses to Amyloid- $\beta^2$ and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders. <i>Journal of Neuroscience</i> , 2011, 31, 4720-4730.	1.7	123
531	The acetylation of tau inhibits its function and promotes pathological tau aggregation. <i>Nature Communications</i> , 2011, 2, 252.	5.8	554
532	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011, 95, 629-635.	2.8	1,278
533	Exogenous $\beta$ -Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. <i>Neuron</i> , 2011, 72, 57-71.	3.8	1,249
534	Characterizing Alzheimer's disease using a hypometabolic convergence index. <i>NeuroImage</i> , 2011, 56, 52-60.	2.1	144
535	Evidence for Ordering of Alzheimer Disease Biomarkers. <i>Archives of Neurology</i> , 2011, 68, 1526.	4.9	195
536	Building an integrated neurodegenerative disease database at an academic health center. <i>Alzheimer's and Dementia</i> , 2011, 7, e84-93.	0.4	63
537	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
538	Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI Data. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 77-90.	1.2	43
539	P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating. <i>PLoS ONE</i> , 2011, 6, e21050.	1.1	160
540	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 726-738.	3.9	343

#	ARTICLE	IF	CITATIONS
541	T1̄-MRI in Alzheimer's Disease: Detection of Pathological Changes in Medial Temporal Lobe. , 2011, 21, e86-e90.		26
542	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
543	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	3.9	102
544	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathologica, 2011, 121, 509-517.	3.9	52
545	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, 2011, 121, 597-609.	3.9	256
546	A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica, 2011, 122, 111-113.	3.9	817
547	Factors affecting Ā <sup>2</sup> plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	3.9	151
548	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathologica, 2011, 122, 737-745.	3.9	15
549	Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. Acta Neuropathologica, 2011, 122, 715-726.	3.9	76
550	T1rho (T1̄) MR imaging in Alzheimer's™ disease and Parkinson's™ disease with and without dementia. Journal of Neurology, 2011, 258, 380-385.	1.8	53
551	Behavioral Variant Frontotemporal Dementia with Corticobasal Degeneration Pathology: Phenotypic Comparison to bvFTD with Pick's™ Disease. Journal of Molecular Neuroscience, 2011, 45, 594-608.	1.1	41
552	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 2011, 69, 655-663.	2.8	126
553	Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 2011, 70, 327-340.	2.8	367
554	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.9	108
555	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	3.7	118
556	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.9	152
557	Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2011, 31, 14436-14449.	1.7	201
558	Intraneuronal APP, Not Free Ā <sup>2</sup> Peptides in 3xTg-AD Mice: Implications for Tau versus Ā <sup>2</sup> -Mediated Alzheimer Neurodegeneration. Journal of Neuroscience, 2011, 31, 7691-7699.	1.7	95



#	ARTICLE	IF	CITATIONS
559	Association Between In Vivo Fluorine 18â€“Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology. <i>Archives of Neurology</i> , 2011, 68, 1398.	4.9	148
560	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of $\beta^2$ -Amyloid 1-42, Total tau, and P-tau<sub>181</sub> for Identifying Alzheimer Disease Amyloid Plaque Pathology. <i>Archives of Neurology</i> , 2011, 68, 1137.	4.9	161
561	Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnesic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2011, 68, 113.	4.9	32
562	Neocortical and hippocampal amyloid- $\beta^2$ and tau measures associate with dementia in the oldest-old. <i>Brain</i> , 2011, 134, 3708-3715.	3.7	82
563	Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006437-a006437.	2.9	101
564	Harnessing neuroplasticity for clinical applications. <i>Brain</i> , 2011, 134, 1591-1609.	3.7	907
565	BACE1 Activity Is Modulated by Cell-Associated Sphingosine-1-Phosphate. <i>Journal of Neuroscience</i> , 2011, 31, 6850-6857.	1.7	157
566	A yeast functional screen predicts new candidate ALS disease genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20881-20890.	3.3	365
567	PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats. <i>PLoS ONE</i> , 2011, 6, e17951.	1.1	73
568	Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. <i>Lecture Notes in Computer Science</i> , 2011, 7012, 27-34.	1.0	53
569	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 308-316.	2.8	160
570	Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. <i>Archives of Neurology</i> , 2010, 67, 1238-50.	4.9	90
571	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 119, 111-122.	3.9	64
572	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. <i>Acta Neuropathologica</i> , 2010, 119, 1-4.	3.9	854
573	Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. <i>Acta Neuropathologica</i> , 2010, 119, 409-419.	3.9	308
574	Novel CSF biomarkers for Alzheimerâ€™s disease and mild cognitive impairment. <i>Acta Neuropathologica</i> , 2010, 119, 669-678.	3.9	164
575	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41.	3.9	222
576	Biomarker discovery for Alzheimerâ€™s disease, frontotemporal lobar degeneration, and Parkinsonâ€™s disease. <i>Acta Neuropathologica</i> , 2010, 120, 385-399.	3.9	79

#	ARTICLE	IF	CITATIONS
577	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology</i> , 2010, 9, 119-128.	4.9	3,792
578	Total and phosphorylated tau protein as biological markers of Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 30-40.	1.2	330
579	Olfactory epithelium amyloid $\beta$ and paired helical filament $\tau$ pathology in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 462-469.	2.8	167
580	Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. <i>Annals of Neurology</i> , 2010, 68, 535-540.	2.8	148
581	Simultaneous HPLC-MS quantification of 8-iso-PGF $_{2\alpha}$ and 8,12-iso-IPF $_{2\alpha}$ in CSF and brain tissue samples with on-line cleanup. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2209-2216.	1.2	25
582	Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects*. <i>Journal of Forensic Sciences</i> , 2010, 55, 642-645.	0.9	8
583	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. <i>Nature</i> , 2010, 466, 1069-1075.	13.7	1,117
584	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	9.4	479
585	Extensive FUS-immunoreactive Pathology in Juvenile Amyotrophic Lateral Sclerosis with Basophilic Inclusions. <i>Brain Pathology</i> , 2010, 20, 1069-1076.	2.1	116
586	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. <i>Neuropathology</i> , 2010, 30, 103-112.	0.7	169
587	The Spectrum of Mutations in Progranulin. <i>Archives of Neurology</i> , 2010, 67, 161-70.	4.9	166
588	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2010, 30, 13861-13866.	1.7	256
589	Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease. , 2010, 2010, 241-244.		2
590	Synergistic Interactions between A $\beta$ , Tau, and I $\beta$ -Synuclein: Acceleration of Neuropathology and Cognitive Decline. <i>Journal of Neuroscience</i> , 2010, 30, 7281-7289.	1.7	462
591	TDP-43 Mediates Degeneration in a Novel <i>Drosophila</i> Model of Disease Caused by Mutations in VCP/p97. <i>Journal of Neuroscience</i> , 2010, 30, 7729-7739.	1.7	243
592	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2010, 133, 3336-3348.	3.7	455
593	Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum. <i>Archives of Neurology</i> , 2010, 67, 688.	4.9	69
594	A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. <i>Brain</i> , 2010, 133, 1391-1402.	3.7	109

#	ARTICLE	IF	CITATIONS
595	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
596	Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation. Journal of Medicinal Chemistry, 2010, 53, 3739-3747.	2.9	47
597	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, 2010, 31, 1340-1354.	1.5	95
598	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiology of Aging, 2010, 31, 1386-1400.	1.5	53
599	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging, 2010, 31, 1284-1303.	1.5	127
600	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	3.8	1,100
601	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 2010, 6, 230-238.	0.4	256
602	O3-03-01: Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort. , 2010, 6, S129-S129.		1
603	A $\beta$ 2 Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. American Journal of Pathology, 2010, 177, 1977-1988.	1.9	179
604	TAR DNA-binding protein 43 in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 211-220.	4.9	396
605	Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, R156-R162.	1.4	281
606	Use of Alzheimer Disease Biomarkers. JAMA - Journal of the American Medical Association, 2009, 302, 436.	3.8	31
607	Effects of $\beta$ -Secretase Inhibition on the Amyloid $\beta$ 2 Isoform Pattern in a Mouse Model of Alzheimer's Disease. Neurodegenerative Diseases, 2009, 6, 258-262.	0.8	28
608	Transactive Response DNA-Binding Protein 43 Burden in Familial Alzheimer Disease and Down Syndrome. Archives of Neurology, 2009, 66, 1483-8.	4.9	61
609	Expression of TDP-43 C-terminal Fragments In Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. Journal of Biological Chemistry, 2009, 284, 8516-8524.	1.6	304
610	A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiology of Disease, 2009, 34, 417-431.	2.1	162
611	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413.	2.8	1,803
612	<i>FGF20</i> and Parkinson's disease: No evidence of association or pathogenicity via $\alpha$ -synuclein expression. Movement Disorders, 2009, 24, 455-459.	2.2	41

#	ARTICLE	IF	CITATIONS
613	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. <i>Acta Neuropathologica</i> , 2009, 117, 15-18.	3.9	377
614	Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. <i>Acta Neuropathologica</i> , 2009, 117, 137-149.	3.9	466
615	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. <i>Journal of Neurology</i> , 2009, 256, 1205-1214.	1.8	167
616	Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 783-793.	21.5	383
617	A Lack of Amyloid $\beta$ Plaques Despite Persistent Accumulation of Amyloid $\beta$ in Axons of Long-Term Survivors of Traumatic Brain Injury. <i>Brain Pathology</i> , 2009, 19, 214-223.	2.1	227
618	Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. <i>Journal of Neurochemistry</i> , 2009, 110, 1339-1351.	2.1	174
619	A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Neurocase</i> , 2009, 15, 235-247.	0.2	30
620	Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. <i>NeuroImage</i> , 2009, 45, 645-655.	2.1	159
621	Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. <i>NeuroImage</i> , 2009, 46, 394-410.	2.1	102
622	Amyotrophic Lateral Sclerosis-Plus Syndrome With TAR DNA-Binding Protein-43 Pathology. <i>Archives of Neurology</i> , 2009, 66, 121-4.	4.9	52
623	Exogenous $\beta$ -synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20051-20056.	3.3	783
624	Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. <i>Archives of Neurology</i> , 2009, 66, 1359-64.	4.9	83
625	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. <i>Archives of Neurology</i> , 2009, 66, 180-9.	4.9	232
626	TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. <i>Acta Neuropathologica</i> , 2008, 115, 305-311.	3.9	58
627	In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6119-6121.	1.0	11
628	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy-Related Pathology in the Dementia Patient. <i>Brain Pathology</i> , 2008, 18, 220-224.	2.1	106
629	A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. <i>FEBS Letters</i> , 2008, 582, 2252-2256.	1.3	94
630	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. <i>Lancet Neurology</i> , The, 2008, 7, 409-416.	4.9	636

#	ARTICLE	IF	CITATIONS
631	Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. <i>Nature Medicine</i> , 2008, 14, 507-509.	15.2	410
632	Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2008, 173, 182-194.	1.9	284
633	Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2008, 173, 1488-1495.	1.9	171
634	fMRI of Alzheimer's disease. <i>NeuroImage</i> , 2008, 41, 1199-1205.	2.1	72
635	New directions for frontotemporal dementia drug discovery. , 2008, 4, 89-93.		29
636	Gene expression changes in the course of normal brain aging are sexually dimorphic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15605-15610.	3.3	520
637	Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies. <i>Journal of Neuroscience</i> , 2008, 28, 12255-12267.	1.7	153
638	Cytoskeletal Requirements in Axonal Transport of Slow Component-b. <i>Journal of Neuroscience</i> , 2008, 28, 5248-5256.	1.7	54
639	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2008, 17, 1349-1362.	1.4	121
640	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 636-41.	4.9	251
641	PENN Neurodegenerative Disease Research " In the Spirit of Benjamin Franklin. <i>NeuroSignals</i> , 2008, 16, 5-10.	0.5	8
642	TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without Amyloidosis. <i>NeuroSignals</i> , 2008, 16, 41-51.	0.5	115
643	Neuroinflammation and Oxidation/Nitration of $\alpha$ -Synuclein Linked to Dopaminergic Neurodegeneration. <i>Journal of Neuroscience</i> , 2008, 28, 7687-7698.	1.7	385
644	TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1481.	4.9	186
645	Two German Kindreds With Familial Amyotrophic Lateral Sclerosis Due to TARDBP Mutations. <i>Archives of Neurology</i> , 2008, 65, 1185-9.	4.9	138
646	Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation. <i>Journal of Biological Chemistry</i> , 2008, 283, 13302-13309.	1.6	509
647	Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 555-564.	0.9	328
648	Dementia. <i>Archives of Neurology</i> , 2008, 65, 593-5.	4.9	22

#	ARTICLE	IF	CITATIONS
649	Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 393-399.	1.2	106
650	TDP-43 immunoreactivity in anoxic, ischemic and proliferating lesion of the central nervous system. <i>FASEB Journal</i> , 2008, 22, 708.13.	0.2	0
651	TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. <i>Archives of Neurology</i> , 2007, 64, 1449.	4.9	61
652	Rapid and Intermittent Cotransport of Slow Component-b Proteins. <i>Journal of Neuroscience</i> , 2007, 27, 3131-3138.	1.7	100
653	Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia. <i>Archives of Neurology</i> , 2007, 64, 1601.	4.9	91
654	TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1388.	4.9	179
655	Clinical, Genetic, and Pathologic Characteristics of Patients With Frontotemporal Dementia and Progranulin Mutations. <i>Archives of Neurology</i> , 2007, 64, 1148.	4.9	52
656	TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 177-183.	0.9	201
657	Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. <i>Neuron</i> , 2007, 53, 337-351.	3.8	1,696
658	High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 1-6.	1.0	97
659	Pesticide Exposure Exacerbates $\tau$ -Synucleinopathy in an A53T Transgenic Mouse Model. <i>American Journal of Pathology</i> , 2007, 170, 658-666.	1.9	117
660	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. <i>American Journal of Pathology</i> , 2007, 171, 227-240.	1.9	446
661	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. <i>Annals of Neurology</i> , 2007, 61, 427-434.	2.8	840
662	Increased levels of fucosyltransferase IX and carbohydrate Lewisx adhesion determinant in human NT2N neurons. <i>Journal of Neuroscience Research</i> , 2007, 85, 1260-1270.	1.3	20
663	Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3642-3646.	1.0	19
664	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 295-303.	21.5	293
665	Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. <i>Nature Reviews Neuroscience</i> , 2007, 8, 663-672.	4.9	1,866
666	TDP-43: a novel neurodegenerative proteinopathy. <i>Current Opinion in Neurobiology</i> , 2007, 17, 548-555.	2.0	113

#	ARTICLE	IF	CITATIONS
667	The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. <i>Neurobiology of Disease</i> , 2007, 25, 561-570.	2.1	231
668	Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual. <i>Acta Neuropathologica</i> , 2007, 113, 471-479.	3.9	12
669	Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2007, 113, 543-548.	3.9	53
670	TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. <i>Acta Neuropathologica</i> , 2007, 114, 63-70.	3.9	198
671	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 5-22.	3.9	978
672	Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. <i>Acta Neuropathologica</i> , 2007, 115, 133-145.	3.9	161
673	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. <i>Acta Neuropathologica</i> , 2007, 114, 221-229.	3.9	378
674	Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. <i>Acta Neuropathologica</i> , 2007, 115, 123-131.	3.9	78
675	Mechanisms of slow axonal transport of $\alpha$ -synuclein. <i>FASEB Journal</i> , 2007, 21, A28.	0.2	0
676	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Science</i> , 2006, 314, 130-133.	6.0	5,422
677	Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous $\alpha$ -Synuclein Inclusions of $\alpha$ -Synucleinopathies. <i>American Journal of Pathology</i> , 2006, 168, 947-961.	1.9	154
678	Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies. <i>American Journal of Pathology</i> , 2006, 169, 1343-1352.	1.9	296
679	Mechanisms of Parkinson's Disease Linked to Pathological $\alpha$ -Synuclein: New Targets for Drug Discovery. <i>Neuron</i> , 2006, 52, 33-38.	3.8	437
680	Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 257-262.	1.2	54
681	Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. <i>Acta Neuropathologica</i> , 2006, 111, 401-412.	3.9	26
682	Characterization of A $\beta$ <sup>211-40/42</sup> peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated A $\beta$ <sup>2</sup> species in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2006, 112, 163-174.	3.9	87
683	Frontotemporal dementia: Clinicopathological correlations. <i>Annals of Neurology</i> , 2006, 59, 952-962.	2.8	444
684	Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. <i>Annals of Neurology</i> , 2006, 60, 335-345.	2.8	38

#	ARTICLE	IF	CITATIONS
685	$\hat{\Gamma}^2$ -synuclein modulates $\hat{\Gamma}^{\pm}$ -synuclein neurotoxicity by reducing $\hat{\Gamma}^{\pm}$ -synuclein protein expression. Human Molecular Genetics, 2006, 15, 3002-3011.	1.4	75
686	Targeting Amyloid- $\hat{\Gamma}^2$ Peptide (A $\hat{\Gamma}^2$ ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in A $\hat{\Gamma}^2$ Precursor Protein (APP) Transgenic Mice. Journal of Biological Chemistry, 2006, 281, 4292-4299.	1.6	246
687	Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes. Journal of Neuroscience, 2006, 26, 644-654.	1.7	109
688	Neuropathologic, Biochemical, and Molecular Characterization of the Frontotemporal Dementias. Journal of Neuropathology and Experimental Neurology, 2005, 64, 420-428.	0.9	92
689	Pathological tau: a loss of normal function or a gain in toxicity?. Nature Neuroscience, 2005, 8, 1136-1137.	7.1	77
690	Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathologica, 2005, 109, 5-13.	3.9	324
691	D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathologica, 2005, 109, 497-502.	3.9	80
692	Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathologica, 2005, 110, 547-556.	3.9	107
693	Frontotemporal lobar degeneration. , 2005, , 481-493.		1
694	Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2. Journal of Neuroscience, 2005, 25, 689-698.	1.7	141
695	BACE overexpression alters the subcellular processing of APP and inhibits A $\hat{\Gamma}^2$ deposition in vivo. Journal of Cell Biology, 2005, 168, 291-302.	2.3	132
696	Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration. Journal of Neuroscience, 2005, 25, 3539-3550.	1.7	166
697	Delayed Transplantation of Human Neurons following Brain Injury in Rats: A Long-Term Graft Survival and Behavior Study. Journal of Neurotrauma, 2005, 22, 1456-1474.	1.7	47
698	Enhanced Neurofibrillary Tangle Formation, Cerebral Atrophy, and Cognitive Deficits Induced by Repetitive Mild Brain Injury in a Transgenic Tauopathy Mouse Model. Journal of Neurotrauma, 2005, 22, 1134-1141.	1.7	120
699	Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies. Journal of Neuroscience, 2005, 25, 9434-9443.	1.7	108
700	Reversible Inhibition of $\hat{\Gamma}^{\pm}$ -Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations*. Journal of Biological Chemistry, 2005, 280, 21212-21219.	1.6	248
701	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 227-231.	3.3	374
702	Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Letters, 2005, 579, 2564-2568.	1.3	47



#	ARTICLE	IF	CITATIONS
703	The Alzheimer's Brain. American Journal of Pathology, 2005, 167, 1183-1188.	1.9	20
704	Impaired Rapid Eye Movement Sleep in the Tg2576 APP Murine Model of Alzheimer's Disease with Injury to Pedunculopontine Cholinergic Neurons. American Journal of Pathology, 2005, 167, 1361-1369.	1.9	74
705	Mouse Model of Multiple System Atrophy $\beta$ -Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration. Neuron, 2005, 45, 847-859.	3.8	277
706	Nosology of Parkinson's Disease: Looking for the Way Out of a Quackmire. Neuron, 2005, 47, 479-482.	3.8	87
707	Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Expert Opinion on Pharmacotherapy, 2005, 6, 683-686.	0.9	55
708	The Art and Science of Anti-Aging Therapies. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe11-pe11.	0.9	1
709	Living Longer and Paying the Price?. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe38-pe38.	0.9	2
710	Important anatomical landmarks in the brain in dementia. , 2004, , 34-47.		0
711	Transgenic mouse models of neurodegenerative disease. , 2004, , 533-557.		0
712	Sporadic tauopathies: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease. , 2004, , 227-256.		18
713	Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Journal of Neurosurgery, 2004, 100, 553-556.	0.9	53
714	17q-Linked Frontotemporal Dementia "Amyotrophic Lateral Sclerosis Without Tau Mutations With Tau and $\beta$ -Synuclein Inclusions. Archives of Neurology, 2004, 61, 398.	4.9	71
715	A Review and Rationale for the Use of Cellular Transplantation as a Therapeutic Strategy for Traumatic Brain Injury. Journal of Neurotrauma, 2004, 21, 1501-1538.	1.7	69
716	Ex Vivo Gene Therapy Using Targeted Engraftment of NGF-Expressing Human NT2N Neurons Attenuates Cognitive Deficits Following Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2004, 21, 1723-1736.	1.7	82
717	Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB Journal, 2004, 18, 1129-1131.	0.2	66
718	Lewy Bodies in the Amygdala. Archives of Neurology, 2004, 61, 1915-9.	4.9	102
719	Early Vitamin E supplementation in young but not aged mice reduces $A\beta$ levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB Journal, 2004, 18, 323-325.	0.2	288
720	Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy. Journal of Neuroscience, 2004, 24, 4657-4667.	1.7	169

#	ARTICLE	IF	CITATIONS
721	Degradative organelles containing mislocalized $\hat{1}\pm$ - and $\hat{1}^2$ -synuclein proliferate in presenilin-1 null neurons. <i>Journal of Cell Biology</i> , 2004, 165, 335-346.	2.3	108
722	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <i>Journal of Neurochemistry</i> , 2004, 90, 1541-1541.	2.1	1
723	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. <i>Nature Medicine</i> , 2004, 10, 1055-1063.	15.2	624
724	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <i>Journal of Neurochemistry</i> , 2004, 90, 758-764.	2.1	147
725	Effects of $\hat{1}\pm$ -tocopherol on an animal model of tauopathies. <i>Free Radical Biology and Medicine</i> , 2004, 37, 176-186.	1.3	92
726	Olfactory dysfunction occurs in transgenic mice overexpressing human $\hat{1}$ , protein. <i>Brain Research</i> , 2004, 1000, 174-178.	1.1	57
727	Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders. <i>Neurochemical Research</i> , 2004, 29, 1053-1064.	1.6	84
728	$\hat{1}$ -Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. <i>Acta Neuropathologica</i> , 2004, 108, 213-23.	3.9	50
729	The cytoskeleton in neurodegenerative diseases. <i>Journal of Pathology</i> , 2004, 204, 438-449.	2.1	156
730	Animal models of neurodegenerative dementing disorders other than Alzheimer's disease. <i>Clinical Neuroscience Research</i> , 2004, 3, 427-427.	0.8	1
731	More than just two peas in a pod: common amyloidogenic properties of tau and $\hat{1}\pm$ -synuclein in neurodegenerative diseases. <i>Trends in Neurosciences</i> , 2004, 27, 129-134.	4.2	177
732	Expression of the Small Heat-Shock Protein $\hat{1}\pm$ B-Crystallin in Tauopathies with Glial Pathology. <i>American Journal of Pathology</i> , 2004, 164, 155-166.	1.9	112
733	Modulation of Nuclear Factor- $\hat{1}^B$ Activity by Indomethacin Influences $\hat{1}^2$ Levels but Not $\hat{1}^2$ Precursor Protein Metabolism in a Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2004, 165, 2197-2206.	1.9	156
734	Long-Term Accumulation of Amyloid- $\hat{1}^2$ , $\hat{1}^2$ -Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma. <i>American Journal of Pathology</i> , 2004, 165, 357-371.	1.9	245
735	12/15-Lipoxygenase Is Increased in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2004, 164, 1655-1662.	1.9	207
736	$\hat{1}\pm$ -Internexin Is Present in the Pathological Inclusions of Neuronal Intermediate Filament Inclusion Disease. <i>American Journal of Pathology</i> , 2004, 164, 2153-2161.	1.9	116
737	Pathobiological features in neurodegenerative diseases: an overview. <i>International Congress Series</i> , 2004, 1260, 69-75.	0.2	2
738	Hereditary tauopathies and idiopathic frontotemporal dementias. , 2004, , 257-288.		9

#	ARTICLE	IF	CITATIONS
739	Vascular dementias. , 2004, , 289-329.		5
740	Familial and sporadic cerebral amyloid angiopathies associated with dementia and the BRI dementias. , 2004, , 330-352.		8
741	Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with $\alpha$ -synuclein inclusions. , 2004, , 353-375.		5
742	Huntington's disease. , 2004, , 376-401.		5
743	Alcoholism and dementia. , 2004, , 427-441.		2
744	Hydrocephalus and dementia. , 2004, , 442-456.		4
745	Schizophrenia and its dementia. , 2004, , 497-508.		1
746	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	3.9	206
747	Morphometric methods and dementia. , 2004, , 75-81.		0
748	Molecular diagnosis of dementia. , 2004, , 91-112.		0
749	Human prion diseases. , 2004, , 402-426.		1
750	Definition, clinical features and neuroanatomical basis of dementia. , 2004, , 1-33.		10
751	Neuroimaging Alzheimer's disease. , 2004, , 128-160.		0
752	Other diseases that cause dementia. , 2004, , 509-532.		0
753	Infectious (and inflammatory) diseases causing dementia. , 2004, , 472-496.		1
754	Neuropathology of the ageing brain. , 2004, , 113-127.		0
755	Down's syndrome and Alzheimer's disease. , 2004, , 207-226.		0
756	Practical approach to pathological diagnosis. , 2004, , 48-74.		0

#	ARTICLE	IF	CITATIONS
757	Head injury and dementia. , 2004, , 457-471.		1
758	Safety precautions in laboratories involved with dementia diagnosis and research. , 2004, , 82-90.		0
759	Protein mis-folding emerges as a "drugable" target for discovery of novel therapies for neuropsychiatric diseases of aging. American Journal of Geriatric Psychiatry, 2004, 12, 134-5.	0.6	5
760	Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. American Journal of Geriatric Psychiatry, 2004, 12, 136-45.	0.6	5
761	Detection of Amyloid Plaques by Radioligands for A $\beta$ <sup>240</sup> and A $\beta$ <sup>242</sup> : Potential Imaging Agents in Alzheimer's Patients. Journal of Molecular Neuroscience, 2003, 20, 15-24.	1.1	41
762	Overview of Protein Aggregation in Single, Double, and Triple Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 1-6.	1.8	35
763	Interactions of Amyloidogenic Proteins. NeuroMolecular Medicine, 2003, 4, 49-58.	1.8	91
764	Protein Accumulation in Traumatic Brain Injury. NeuroMolecular Medicine, 2003, 4, 59-72.	1.8	126
765	Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathologica, 2003, 105, 177-184.	3.9	29
766	Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathologica, 2003, 105, 469-476.	3.9	51
767	Expression of $\alpha$ -, $\beta$ -, and $\gamma$ -synuclein in glial tumors and medulloblastomas. Acta Neuropathologica, 2003, 106, 167-175.	3.9	76
768	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathologica, 2003, 106, 243-250.	3.9	36
769	Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. Journal of Comparative Neurology, 2003, 456, 176-183.	0.9	91
770	Distinct cleavage patterns of normal and pathologic forms of $\beta$ -synuclein by calpain I in vitro. Journal of Neurochemistry, 2003, 86, 836-847.	2.1	147
771	A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. Journal of Neurochemistry, 2003, 86, 1359-1368.	2.1	124
772	Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein. Science, 2003, 300, 636-640.	6.0	791
773	Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies. American Journal of Pathology, 2003, 163, 1021-1031.	1.9	183
774	Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density. American Journal of Pathology, 2003, 163, 1615-1621.	1.9	76

#	ARTICLE	IF	CITATIONS
775	Ubiquitination of $\hat{\alpha}$ -Synuclein Is Not Required for Formation of Pathological Inclusions in $\hat{\alpha}$ -Synucleinopathies. <i>American Journal of Pathology</i> , 2003, 163, 91-100.	1.9	129
776	Rotenone Neurotoxicity: A New Window on Environmental Causes of Parkinson's Disease and Related Brain Amyloidoses. <i>Experimental Neurology</i> , 2003, 179, 6-8.	2.0	27
777	Biological markers for therapeutic trials in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 521-536.	1.5	249
778	$\hat{\alpha}$ -Unfolding pathways in neurodegenerative disease. <i>Trends in Neurosciences</i> , 2003, 26, 407-410.	4.2	174
779	Neurodegeneration and defective neurotransmission in a <i>Caenorhabditis elegans</i> model of tauopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9980-9985.	3.3	336
780	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. <i>Journal of Biological Chemistry</i> , 2003, 278, 48120-48128.	1.6	140
781	Genetically Modified NT2N Human Neuronal Cells Mediate Long-Term Gene Expression as CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental Traumatic Brain Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 368-380.	0.9	84
782	Cerebrospinal Fluid Tau and $\hat{\beta}$ -Amyloid. <i>Archives of Neurology</i> , 2003, 60, 1696.	4.9	341
783	Familial Frontotemporal Dementia: From Gene Discovery to Clinical Molecular Diagnostics. <i>Clinical Chemistry</i> , 2003, 49, 1717-1725.	1.5	20
784	Molecular Identification of AMY, an Alzheimer Disease Amyloid-Associated Protein. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 1108-1117.	0.9	18
785	Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic Acid. <i>Journal of Neuroscience</i> , 2003, 23, 8872-8880.	1.7	67
786	Reduction of Detyrosinated Microtubules and Golgi Fragmentation Are Linked to Tau-Induced Degeneration in Astrocytes. <i>Journal of Neuroscience</i> , 2003, 23, 10662-10671.	1.7	75
787	Parkinson's Disease and Related $\hat{\alpha}$ -Synucleinopathies Are Brain Amyloidoses. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 107-110.	1.8	139
788	Phosphorylated $\hat{\alpha}$ -Synuclein Is Ubiquitinated in $\hat{\alpha}$ -Synucleinopathy Lesions. <i>Journal of Biological Chemistry</i> , 2002, 277, 49071-49076.	1.6	365
789	Increase of Brain Oxidative Stress in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2002, 59, 972.	4.9	574
790	Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. <i>FASEB Journal</i> , 2002, 16, 1138-1140.	0.2	252
791	Tau and $\hat{\alpha}$ -Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam. <i>American Journal of Pathology</i> , 2002, 160, 1725-1731.	1.9	115
792	Signature Tau Neuropathology in Gray and White Matter of Corticobasal Degeneration. <i>American Journal of Pathology</i> , 2002, 160, 2045-2053.	1.9	136

#	ARTICLE	IF	CITATIONS
793	Clonal Human (hNT) Neuron Grafts for Stroke Therapy. <i>American Journal of Pathology</i> , 2002, 160, 1201-1206.	1.9	240
794	Biochemical Analysis of I $\beta$ , Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease. <i>American Journal of Pathology</i> , 2002, 161, 1135-1141.	1.9	71
795	Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2002, 160, 409-411.	1.9	9
796	Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam. <i>Experimental Neurology</i> , 2002, 176, 1-11.	2.0	36
797	Chaperone Suppression of alpha -Synuclein Toxicity in a Drosophila Model for Parkinson's Disease. <i>Science</i> , 2002, 295, 865-868.	6.0	1,206
798	Neuronal I $\beta$ -Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human I $\beta$ -Synuclein. <i>Neuron</i> , 2002, 34, 521-533.	3.8	1,094
799	Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration. <i>Neuron</i> , 2002, 35, 433-446.	3.8	142
800	Parkinson's Disease and Related Synucleinopathies are a New Class of Nervous System Amyloidoses. <i>NeuroToxicology</i> , 2002, 23, 457-460.	1.4	63
801	The role of tau in Alzheimer's disease. <i>Medical Clinics of North America</i> , 2002, 86, 615-627.	1.1	62
802	Repetitive Mild Brain Trauma Accelerates A $\beta$ <sup>2</sup> Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis. <i>Journal of Neuroscience</i> , 2002, 22, 446-454.	1.7	314
803	IMPY: an improved thioflavin-T derivative for in vivo labeling of I $\beta$ -amyloid plaques. <i>Brain Research</i> , 2002, 956, 202-210.	1.1	204
804	Global democratic consensus on neuropathological disease criteria. <i>Lancet Neurology</i> , The, 2002, 1, 340.	4.9	3
805	The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases <sup>1,2</sup> 11 Guest Editors: Mark A. Smith and George Perry 22 This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease." The full list of papers may be found on the homepage of the journal.. <i>Free Radical Biology and Medicine</i> , 2002, 33, 1264-1275.	1.3	252
806	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. <i>Annals of Neurology</i> , 2002, 52, 205-210.	2.8	300
807	Tauists, Baptists, Syners, Apostates, and new data. <i>Annals of Neurology</i> , 2002, 52, 263-265.	2.8	54
808	Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 7-10.	1.1	31
809	Co-occurrence of Parkinson's disease with progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2002, 103, 526-530.	3.9	28
810	Concurrence of I $\beta$ -synuclein and tau brain pathology in the Contursi kindred. <i>Acta Neuropathologica</i> , 2002, 104, 7-11.	3.9	247

#	ARTICLE	IF	CITATIONS
811	Tau and Axonopathy in Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2002, 2, 131-150.	1.8	120
812	Misfolded proteinase K-resistant hyperphosphorylated $\beta$ -synuclein in aged transgenic mice with locomotor deterioration and in human $\beta$ -synucleinopathies. <i>Journal of Clinical Investigation</i> , 2002, 110, 1429-1439.	3.9	292
813	Neurodegenerative Tauopathies. <i>Annual Review of Neuroscience</i> , 2001, 24, 1121-1159.	5.0	2,416
814	A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of $\beta$ -Synuclein Is Essential for Filament Assembly. <i>Journal of Biological Chemistry</i> , 2001, 276, 2380-2386.	1.6	865
815	Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. <i>New England Journal of Medicine</i> , 2001, 344, 710-719.	13.9	2,253
816	The Fluorescent Congo Red Derivative, (Trans,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 552 Td (Trans) $\beta$ -1-Bromo-2,5-Bis-(3-Hydroxycarbonyl-4-Hydroxy)styrylbenzene Sheet Structures in Postmortem Human Neurodegenerative Disease Brains. <i>American Journal of Pathology</i> , 2001, 159, 937-943.	1.9	81
817	Selective Insolubility of $\beta$ -Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model. <i>American Journal of Pathology</i> , 2001, 159, 2215-2225.	1.9	235
818	Age-Dependent Induction of Congophilic Neurofibrillary Tau Inclusions in Tau Transgenic Mice. <i>American Journal of Pathology</i> , 2001, 158, 555-562.	1.9	167
819	IBOX(2-(4-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. <i>Nuclear Medicine and Biology</i> , 2001, 28, 887-894.	0.3	111
820	Isomerization of (Z,Z) to (E,E) 1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in Strong Base: A Probes for Amyloid Plaques in the Brain. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2270-2275.	2.9	49
821	Induction of $\beta$ -Synuclein Aggregation by Intracellular Nitrate Insult. <i>Journal of Neuroscience</i> , 2001, 21, 8053-8061.	1.7	412
822	Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments. <i>Journal of Neuroscience</i> , 2001, 21, 6026-6035.	1.7	71
823	p38 Mitogen-activated Protein Kinase-independent Induction of gadd45 Expression in Nerve Growth Factor-induced Apoptosis in Medulloblastomas. <i>Journal of Biological Chemistry</i> , 2001, 276, 41120-41127.	1.6	17
824	Spinal Cord Neurofibrillary Pathology in Alzheimer Disease and Guam Parkinsonism-Dementia Complex. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 1075-1086.	0.9	44
825	Update on the Neuropathological Diagnosis of Frontotemporal Dementias. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 1123-1126.	0.9	76
826	Brain degeneration linked to "fatal attractions" of proteins in Alzheimer's disease and related disorders. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 117-119.	1.2	14
827	Frontotemporal dementia and tauopathy. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 413-421.	2.0	32
828	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. <i>Annals of Neurology</i> , 2001, 49, 165-175.	2.8	159

#	ARTICLE	IF	CITATIONS
829	Lewy Body Pathology in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 225-232.	1.1	138
830	A Review and Rationale for the Use of Genetically Engineered Animals in the Study of Traumatic Brain Injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1241-1258.	2.4	42
831	Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. <i>Brain Research</i> , 2001, 914, 48-56.	1.1	150
832	Synucleinopathies: a pathological and molecular review. <i>Clinical Neuroscience Research</i> , 2001, 1, 445-455.	0.8	20
833	Synucleinopathies. <i>Archives of Neurology</i> , 2001, 58, 186.	4.9	437
834	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. <i>Archives of Neurology</i> , 2001, 58, 383-7.	4.9	143
835	Mild head injury increasing the brain's vulnerability to a second concussive impact. <i>Journal of Neurosurgery</i> , 2001, 95, 859-870.	0.9	278
836	Synucleins Are Developmentally Expressed, and $\beta$ -Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons. <i>Journal of Neuroscience</i> , 2000, 20, 3214-3220.	1.7	795
837	Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of $\beta$ -Synuclein Permutations in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 830-841.	0.9	135
838	Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. , 2000, 88, 2154-2163.		145
839	A panel of epitope-specific antibodies detects protein domains distributed throughout human $\beta$ -synuclein in lewy bodies of Parkinson's disease. , 2000, 59, 528-533.		197
840	Neuropathology of synuclein aggregates. <i>Journal of Neuroscience Research</i> , 2000, 61, 121-127.	1.3	275
841	$\beta$ -synuclein is developmentally expressed in cultured rat brain oligodendrocytes. <i>Journal of Neuroscience Research</i> , 2000, 62, 9-14.	1.3	125
842	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. <i>Annals of Neurology</i> , 2000, 48, 77-87.	2.8	310
843	Frontotemporal dementia with novel tau pathology and a Glu342Valtau mutation. <i>Annals of Neurology</i> , 2000, 48, 850-858.	2.8	97
844	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. <i>Oncogene</i> , 2000, 19, 2043-2051.	2.6	86
845	A Novel Apoptotic Pathway Induced by Nerve Growth Factor-mediated TrkA Activation in Medulloblastoma. <i>Journal of Biological Chemistry</i> , 2000, 275, 565-570.	1.6	54
846	Long-term deep brain stimulation in a patient with essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral thalamus. <i>Journal of Neurosurgery</i> , 2000, 93, 140-144.	0.9	66



#	ARTICLE	IF	CITATIONS
847	Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: Implications for improving therapy of spinal cord injury. <i>Progress in Brain Research</i> , 2000, 128, 299-307.	0.9	31
848	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1627-1637.	1.3	77
849	Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by $\hat{1}\pm$ , $\hat{1}^2$ , and $\hat{1}^3$ -Synuclein Neuropathology. <i>American Journal of Pathology</i> , 2000, 157, 361-368.	1.9	190
850	Widespread Nitration of Pathological Inclusions in Neurodegenerative Synucleinopathies. <i>American Journal of Pathology</i> , 2000, 157, 1439-1445.	1.9	256
851	A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. <i>Neurochemistry International</i> , 2000, 37, 17-31.	1.9	62
852	Quantitative neurohistological features of frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2000, 21, 913-919.	1.5	70
853	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. <i>Journal of Chemical Neuroanatomy</i> , 2000, 20, 225-244.	1.0	46
854	Oxidative Damage Linked to Neurodegeneration by Selective alpha -Synuclein Nitration in Synucleinopathy Lesions. <i>Science</i> , 2000, 290, 985-989.	6.0	1,498
855	"Fatal Attractions" of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Annals of the New York Academy of Sciences</i> , 2000, 924, 62-67.	1.8	154
856	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		1
857	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		4
858	Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. <i>Annals of Neurology</i> , 2000, 48, 850-858.	2.8	5
859	Elevated Levels of Tau in Cerebrospinal Fluid: Implications for the Antemortem Diagnosis of Alzheimer's Disease*. <i>Journal of Alzheimer's Disease</i> , 1999, 1, 297-305.	1.2	15
860	Tau Pathology in a Family with Dementia and a P301L Mutation in Tau. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 335-345.	0.9	170
861	Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats. <i>Journal of Neurosurgery</i> , 1999, 90, 116-124.	0.9	72
862	Toxicologic and Carcinogenic Effects of the Type IV Phosphodiesterase Inhibitor RP 73401 on the Nasal Olfactory Tissue in Rats. <i>Toxicologic Pathology</i> , 1999, 27, 383-394.	0.9	25
863	Terminally Differentiated Human Neurons Survive and Integrate Following Transplantation into the Traumatically Injured Rat Brain. <i>Journal of Neurotrauma</i> , 1999, 16, 403-414.	1.7	53
864	Transgenic Models of Tauopathies and Synucleinopathies. <i>Brain Pathology</i> , 1999, 9, 733-739.	2.1	31

#	ARTICLE	IF	CITATIONS
865	High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. <i>Nature Biotechnology</i> , 1999, 17, 53-57.	9.4	38
866	Increased Vulnerability of NFH-LacZ Transgenic Mouse to Traumatic Brain Injury-Induced Behavioral Deficits and Cortical Damage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 762-770.	2.4	45
867	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. <i>Annals of Neurology</i> , 1999, 45, 174-181.	2.8	121
868	Antibodies to $\tau$ -synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 45, 353-357.	2.8	289
869	Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. <i>Annals of Neurology</i> , 1999, 46, 271-273.	2.8	46
870	Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT)., 1999, 415, 404-418.		36
871	[6] Purification of paired helical filament tau and normal tau from human brain tissue. <i>Methods in Enzymology</i> , 1999, 309, 81-89.	0.4	48
872	Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform. <i>Neuron</i> , 1999, 24, 751-762.	3.8	564
873	Epitope mapping of LB509, a monoclonal antibody directed against human $\tau$ -synuclein. <i>Neuroscience Letters</i> , 1999, 269, 13-16.	1.0	96
874	Phospholipase pathway in Alzheimer's disease brains: decrease in $\text{G}\beta$ 1 in dorsolateral prefrontal cortex. <i>Molecular Brain Research</i> , 1999, 66, 188-190.	2.5	8
875	Mutant and Wild Type Human $\tau$ -Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro. <i>Journal of Biological Chemistry</i> , 1999, 274, 7619-7622.	1.6	478
876	The Levels of Soluble versus Insoluble Brain $\text{A}\beta$ 2 Distinguish Alzheimer's Disease from Normal and Pathologic Aging. <i>Experimental Neurology</i> , 1999, 158, 328-337.	2.0	490
877	The Role of Calpain-Mediated Spectrin Proteolysis in Traumatically Induced Axonal Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 365-375.	0.9	226
878	Spatial Relationship of AMY Protein Deposits and Different Species of $\text{A}\beta$ 2 Peptides in Amyloid Plaques of the Alzheimer Disease Brain. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 1227-1233.	0.9	9
879	Accumulation of Intracellular Amyloid- $\beta$ Peptide ( $\text{A}\beta$ 1-40) in Mucopolysaccharidosis Brains. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 815-824.	0.9	52
880	A distinct familial presenile dementia with a novel missense mutation in the tau gene. <i>NeuroReport</i> , 1999, 10, 497-501.	0.6	156
881	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. <i>Annals of Neurology</i> , 1999, 45, 174-181.	2.8	4
882	Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. <i>Nature</i> , 1998, 393, 702-705.	13.7	3,333

#	ARTICLE	IF	CITATIONS
883	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. <i>Cell Death and Differentiation</i> , 1998, 5, 832-837.	5.0	272
884	Cellular and Molecular Neuropathology of the Olfactory Epithelium and Central Olfactory Pathways in Alzheimer's Disease and Schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 1998, 855, 762-775.	1.8	69
885	Neural differentiation of rhesus embryonic stem cells. <i>Apmis</i> , 1998, 106, 149-157.	0.9	52
886	Characterization of unmyelinated axons uniting epidermal and dermal immune cells in primate and murine skin. <i>Journal of Cutaneous Pathology</i> , 1998, 25, 20-29.	0.7	75
887	Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. <i>Annals of Neurology</i> , 1998, 43, 259-265.	2.8	55
888	Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble $\alpha$ -synuclein. <i>Annals of Neurology</i> , 1998, 44, 415-422.	2.8	633
889	Twofold overexpression of human $\alpha$ -amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. , 1998, 392, 428-438.		83
890	RNA sequestration to pathological lesions of neurodegenerative diseases. <i>Acta Neuropathologica</i> , 1998, 96, 487-494.	3.9	126
891	Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. <i>Lancet, The</i> , 1998, 351, 884.	6.3	54
892	Brain Trauma Induces Massive Hippocampal Neuron Death Linked to a Surge in $\beta$ -Amyloid Levels in Mice Overexpressing Mutant Amyloid Precursor Protein. <i>American Journal of Pathology</i> , 1998, 153, 1005-1010.	1.9	148
893	Lewy Bodies Contain Altered $\alpha$ -Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. <i>American Journal of Pathology</i> , 1998, 153, 1365-1370.	1.9	484
894	Aggregation of Neurofilament and $\alpha$ -Synuclein Proteins in Lewy Bodies. <i>Archives of Neurology</i> , 1998, 55, 151.	4.9	249
895	Human Olfactory Mucosa in Schizophrenia. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 1998, 107, 349-355.	0.6	23
896	Toxicity and Neuronal Infection of a HSV-1 ICP34.5 Mutant in Nude Mice. <i>Journal of NeuroVirology</i> , 1998, 4, 100-105.	1.0	29
897	A New Consensus Report on Biomarkers for the Early Antemortem Diagnosis of Alzheimer Disease: Current Status, Relevance to Drug Discovery, and Recommendations for Future Research. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 643-644.	0.9	23
898	Quantification of Modified Amyloid $\beta$ Peptides in Alzheimer Disease and Down Syndrome Brains. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 1089-1095.	0.9	71
899	Cerebral ischemia and CNS transplantation. <i>NeuroReport</i> , 1998, 9, 3703-3709.	0.6	98
900	Experimental Brain Injury Induces Regionally Distinct Apoptosis during the Acute and Delayed Post-Traumatic Period. <i>Journal of Neuroscience</i> , 1998, 18, 5663-5672.	1.7	495

#	ARTICLE	IF	CITATIONS
901	Increased F <sub>2</sub> -isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation <i>in vivo</i> . <i>FASEB Journal</i> , 1998, 12, 1777-1783.	0.2	396
902	Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation. <i>Journal of Cell Biology</i> , 1997, 139, 1307-1315.	2.3	267
903	Progressive Atrophy and Neuron Death for One Year Following Brain Trauma in the Rat. <i>Journal of Neurotrauma</i> , 1997, 14, 715-727.	1.7	398
904	Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1228-1231.	1.3	18
905	Apolipoprotein E genotype in schizophrenia. <i>NeuroReport</i> , 1997, 8, 1523-1526.	0.6	34
906	Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 1095-1097.	0.9	872
907	Improvement of cognitive deficits and decreased cholinergic neuronal cell loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury. <i>Journal of Neurosurgery</i> , 1997, 86, 511-518.	0.9	139
908	Cerebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology. <i>Biochemical and Biophysical Research Communications</i> , 1997, 236, 262-264.	1.0	162
909	Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells). <i>Journal of Neuroscience</i> , 1997, 17, 5726-5737.	1.7	137
910	Selective Degeneration of Purkinje Cells with Lewy Body-Like Inclusions in Aged NFHLACZ Transgenic Mice. <i>Journal of Neuroscience</i> , 1997, 17, 1064-1074.	1.7	66
911	Nerve Growth Factor Induces Apoptosis in Human Medulloblastoma Cell Lines that Express TrkA Receptors. <i>Journal of Neuroscience</i> , 1997, 17, 530-542.	1.7	114
912	Amyloid $\beta$ -Protein (A $\beta$ ) 1-40 But Not A $\beta$ 1-42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain. <i>Journal of Neuroscience</i> , 1997, 17, 8187-8193.	1.7	101
913	$\beta$ -Synuclein in Lewy bodies. <i>Nature</i> , 1997, 388, 839-840.	13.7	7,181
914	Primitive Neuroectodermal Tumors of the Central Nervous System. <i>Brain Pathology</i> , 1997, 7, 765-784.	2.1	97
915	Coordinate reduction in cell proliferation and cell death in mouse olfactory epithelium from birth to maturity. <i>Brain Research</i> , 1997, 761, 347-351.	1.1	27
916	Internexin, MAP1B, and nestin in cortical dysplasia as markers of developmental maturity. <i>Acta Neuropathologica</i> , 1997, 93, 619-627.	3.9	83
917	Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. <i>Annals of Neurology</i> , 1997, 41, 200-209.	2.8	153
918	Genetic evidence for the involvement of ? in progressive supranuclear palsy. <i>Annals of Neurology</i> , 1997, 41, 277-281.	2.8	433

#	ARTICLE	IF	CITATIONS
919	Monoclonal antibodies to purified cortical lewy bodies recognize the mid-size neurofilament subunit. <i>Annals of Neurology</i> , 1997, 42, 595-603.	2.8	48
920	Neurotrophin signal transduction in medulloblastoma. <i>Journal of Neuroscience Research</i> , 1997, 49, 522-527.	1.3	25
921	Neurotrophin signal transduction in medulloblastoma. <i>Journal of Neuroscience Research</i> , 1997, 49, 522-527.	1.3	1
922	The older rabbit as an animal model: Implications for Alzheimer's disease. <i>Neurobiology of Aging</i> , 1996, 17, 283-290.	1.5	52
923	Rational design of an animal model for alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. <i>Neurobiology of Aging</i> , 1996, 17, 173-182.	1.5	30
924	Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains. <i>Annals of the New York Academy of Sciences</i> , 1996, 786, 195-205.	1.8	14
925	Human fetal hippocampal development: I. Cytoarchitecture, myeloarchitecture, and neuronal morphologic features. <i>Journal of Comparative Neurology</i> , 1996, 367, 274-292.	0.9	193
926	Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1. <i>Journal of Neuroscience</i> , 1996, 16, 5644-5653.	1.7	37
927	Neurofibrillary Tangles in Progressive Supranuclear Palsy Contain the Same Tau Epitopes Identified in Alzheimer's Disease PHFtau. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 534-539.	0.9	70
928	Production and Characterization of Two Ependymoma Xenografts. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 540-548.	0.9	14
929	Therapy of a Murine Model of Pediatric Brain Tumors using a Herpes Simplex Virus Type-1 ICP34.5 Mutant and Demonstration of Viral Replication within the CNS. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 1259-1269.	0.9	44
930	TEMPORAL PROGRESSION OF HIPPOCAMPAL ATROPHY AND APOLIPOPROTEIN E GENE IN ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 216-217.	1.3	9
931	Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. <i>Acta Neuropathologica</i> , 1996, 91, 269-277.	3.9	106
932	Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. <i>Acta Neuropathologica</i> , 1996, 91, 475-481.	3.9	116
933	Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. <i>Annals of Neurology</i> , 1996, 39, 481-489.	2.8	70
934	Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 1996, 39, 767-778.	2.8	819
935	Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. <i>Annals of Neurology</i> , 1996, 40, 379-386.	2.8	163
936	Human fetal hippocampal development: II. The neuronal cytoskeleton. , 1996, 367, 293-307.		83

#	ARTICLE	IF	CITATIONS
937	Long-term integration and neuronal differentiation of human embryonal carcinoma cells (NT era-2) transplanted into the caudoputamen of nude mice. , 1996, 376, 603-613.		76
938	Cognitive Impairment in Elderly Schizophrenia: A Dementia (Still) Lacking Distinctive Histopathology. Schizophrenia Bulletin, 1996, 22, 5-9.	2.3	44
939	The apolipoprotein E gene in Binswanger's disease and vascular dementia. Clinical Genetics, 1996, 50, 459-461.	1.0	24
940	The cellular and molecular biology of medulloblastoma. Current Opinion in Neurology, 1995, 8, 437-440.	1.8	9
941	Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau. Journal of Biological Chemistry, 1995, 270, 18917-18922.	1.6	319
942	Animal Models of Medulloblastomas and Related Primitive Neuroectodermal Tumors. A Review. Journal of Neuropathology and Experimental Neurology, 1995, 54, 285-296.	0.9	47
943	Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Annals of Neurology, 1995, 38, 649-652.	2.8	293
944	Expression of trk receptors in the developing and adult human central and peripheral nervous system. Journal of Comparative Neurology, 1995, 356, 387-397.	0.9	96
945	Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain. Journal of Comparative Neurology, 1995, 357, 618-632.	0.9	182
946	Human neurons that constitutively secrete A $\beta$ 2 do not induce Alzheimer's disease pathology following transplantation and long-term survival in the rodent brain. Brain Research, 1995, 671, 333-337.	1.1	22
947	Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases.. FASEB Journal, 1995, 9, 1570-1576.	0.2	206
948	A $\beta$ -Amyloid Peptide and Amyloid Precursor Proteins in Olfactory Mucosa of Patients with Alzheimer's Disease, Parkinson's Disease, and down Syndrome. Annals of Otolaryngology, Rhinology and Laryngology, 1995, 104, 655-661.	0.6	50
949	Studies of childhood brain tumors using immunohistochemistry and microwave technology: methodological considerations. Journal of Neuroscience Methods, 1994, 55, 191-200.	1.3	22
950	In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood. Molecular and Chemical Neuropathology, 1994, 21, 219-239.	1.0	25
951	Apolipoprotein E $\epsilon$ 4 allele distribution in alcoholic dementia and in Alzheimer's disease in Japan. Annals of Neurology, 1994, 36, 797-799.	2.8	24
952	Primitive neuroectodermal tumors of the central nervous system in childhood: tumor biological aspects. Critical Reviews in Oncology/Hematology, 1994, 17, 1-25.	2.0	21
953	Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron, 1994, 13, 989-1002.	3.8	589
954	Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiology of Aging, 1994, 15, 299-303.	1.5	56

#	ARTICLE	IF	CITATIONS
955	Expression of $\beta$ -amyloid precursor protein in the developing human spinal cord. <i>Brain Research</i> , 1994, 642, 132-136.	1.1	17
956	An extensive network of PHF $\tau$ -rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. <i>FEBS Letters</i> , 1994, 344, 69-73.	1.3	50
957	Development and in vitro Characterization of a Cationized Monoclonal Antibody against $\beta$ A4 Protein: A Potential Probe for Alzheimer's Disease. <i>Bioconjugate Chemistry</i> , 1994, 5, 119-125.	1.8	31
958	Cerebellar Dysplasias in Humans: Development and Possible Relationship to Glial and Primitive Neuroectodermal Tumors of the Cerebellar Vermis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994, 53, 61-71.	0.9	55
959	$\tau$ , Phosphorylation in Human, Primate, and Rat Brain: Evidence that a Pool of $\tau$ , Is Highly Phosphorylated In Vivo and Is Rapidly Dephosphorylated In Vitro. <i>Journal of Neurochemistry</i> , 1994, 63, 2279-2287.	2.1	69
960	Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias. <i>Annals of the New York Academy of Sciences</i> , 1994, 747, 92-109.	1.8	44
961	Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. <i>Journal of Comparative Neurology</i> , 1993, 329, 328-336.	0.9	67
962	Expression of neuronal and glial polypeptides during histogenesis of the human cerebellar cortex including observations on the dentate nucleus. <i>Journal of Comparative Neurology</i> , 1993, 334, 356-369.	0.9	80
963	Endoscopic Human Olfactory Biopsy Technique. <i>Laryngoscope</i> , 1993, 103, 815-819.	1.1	32
964	Continuity of neuropil threads with tangle-bearing and tangle-free neurons in Alzheimer disease cortex. <i>Molecular and Chemical Neuropathology</i> , 1993, 18, 299-312.	1.0	22
965	A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. <i>Brain Research</i> , 1993, 616, 325-329.	1.1	54
966	Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. <i>Brain Research</i> , 1993, 618, 333-337.	1.1	88
967	Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding. <i>Neuron</i> , 1993, 10, 1089-1099.	3.8	845
968	Altered $\tau$ and Neurofilament Proteins in Neurodegenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias. <i>Brain Pathology</i> , 1993, 3, 45-54.	2.1	230
969	The disordered neuronal cytoskeleton in Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 1992, 2, 653-656.	2.0	120
970	Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. <i>Brain Research</i> , 1992, 585, 386-390.	1.1	49
971	Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. <i>Molecular and Chemical Neuropathology</i> , 1992, 17, 121-135.	1.0	47
972	Regional distribution and partial molecular characterization of CD4-related mRNA in human brain and peripheral tissues. <i>Molecular Brain Research</i> , 1991, 10, 23-31.	2.5	9

#	ARTICLE	IF	CITATIONS
973	Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes. <i>Brain Research</i> , 1991, 556, 181-195.	1.1	41
974	Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies. <i>Journal of Comparative Neurology</i> , 1991, 309, 150-160.	0.9	105
975	Molecular milestones that signal axonal maturation and the commitment of human spinal cord precursor cells to the neuronal or glial phenotype in development. <i>Journal of Comparative Neurology</i> , 1991, 310, 285-299.	0.9	93
976	Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders. <i>Journal of Comparative Neurology</i> , 1991, 310, 365-376.	0.9	115
977	Neurofilament and chromogranin expression in normal and neoplastic neuroendocrine cells of the human gastrointestinal tract and pancreas. <i>Cancer</i> , 1990, 65, 1219-1227.	2.0	28
978	Antibodies to the I <sup>2</sup> -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. <i>FEBS Letters</i> , 1990, 264, 43-47.	1.3	24
979	Selective Expression of Epitopes in Multiphosphorylation Repeats of the High and Middle Molecular Weight Neurofilament Proteins in Alzheimer Neurofibrillary Tangles. <i>Annals of Medicine</i> , 1989, 21, 113-116.	1.5	11
980	Distribution of phosphate-independent MAP2 epitopes revealed with monoclonal antibodies in microwave-denatured human nervous system tissues. <i>Journal of Neuroscience Methods</i> , 1989, 29, 171-180.	1.3	50
981	Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts. <i>Journal of Neuropathology and Experimental Neurology</i> , 1989, 48, 48-68.	0.9	72
982	Expression of Neurofilament Proteins in the Hypertrophic Granule Cells of Lhermitte-Duclos Disease: An Explanation for the Mass Effect and the Myelination of Parallel Fibers in the Disease State. <i>Journal of Neuropathology and Experimental Neurology</i> , 1988, 47, 206-216.	0.9	34
983	A quantitative correlation of substance P-, calcitonin gene-related peptide- and cholecystokinin-like immunoreactivity with retrogradely labeled trigeminal ganglion cells innervating the eye. <i>Brain Research</i> , 1987, 405, 220-226.	1.1	44
984	Enzymatic detection of native and derivatized horseradish peroxidase in sodium dodecyl sulfate polyacrylamide gels. <i>Analytical Biochemistry</i> , 1986, 155, 371-375.	1.1	12
985	Expression of neurofilament and neuron-specific enolase in small cell tumors of skin using immunohistochemistry. <i>Cancer</i> , 1985, 56, 625-631.	2.0	45
986	Expression of Neurofilament Antigens by Normal and Neoplastic Human Adrenal Chromaffin Cells. <i>New England Journal of Medicine</i> , 1985, 313, 101-104.	13.9	38
987	Familial pineoblastoma. <i>Journal of Neurosurgery</i> , 1985, 62, 930-932.	0.9	16
988	Domain structure of neurofilament subunits as revealed by monoclonal antibodies. <i>Journal of Cellular Biochemistry</i> , 1985, 27, 181-187.	1.2	5
989	Native and derivatized lectins for in vivo studies of neuronal connectivity and neuronal cell biology. <i>Journal of Neuroscience Methods</i> , 1983, 9, 185-204.	1.3	102
990	A morphometric study of the endocytosis of wheat germ agglutinin-horseradish peroxidase conjugates by retinal ganglion cells in the rat. <i>Brain Research</i> , 1983, 272, 201-210.	1.1	30



#	ARTICLE	IF	CITATIONS
991	Time of arrival of wheat germ agglutinin-HRP conjugates in superior colliculus after intraocular injections in the rat. <i>Brain Research</i> , 1983, 267, 365-370.	1.1	14
992	Neuronal Origin of Human Esthesioneuroblastoma Demonstrated with Anti-Neurofilament Monoclonal Antibodies. <i>New England Journal of Medicine</i> , 1982, 307, 159-161.	13.9	76
993	Horseradish peroxidase (HRP) conjugates of cholera toxin and lectins are more sensitive retrogradely transported markers than free HRP. <i>Brain Research</i> , 1982, 231, 33-50.	1.1	146
994	Cholera toxin and wheat germ agglutinin conjugates as neuroanatomical probes: Their uptake and clearance, transganglionic and retrograde transport and sensitivity. <i>Brain Research</i> , 1982, 243, 215-224.	1.1	152
995	Malignant pineocytoma with prominent papillary features. <i>Cancer</i> , 1982, 50, 1789-1793.	2.0	44
996	Conjugates of horseradish peroxidase (HRP) with cholera toxin and wheat germ agglutinin are superior to free HRP as orthogradely transported markers. <i>Brain Research</i> , 1981, 223, 381-385.	1.1	145
997	Neuroanatomical correlates of selective downgaze paralysis. <i>Journal of the Neurological Sciences</i> , 1981, 52, 91-101.	0.3	28
998	A light and electron microscopic study of the intraneuronal transport of horseradish peroxidase and wheat germ agglutinin-peroxidase conjugates in the rat visual system. <i>Journal of Neurocytology</i> , 1981, 10, 441-456.	1.6	50
999	Prefrontal granular cortex of the rhesus monkey. I. Intrahemispheric cortical afferents. <i>Brain Research</i> , 1977, 132, 209-233.	1.1	190
1000	Prefrontal granular cortex of the rhesus monkey. II. Interhemispheric cortical afferents. <i>Brain Research</i> , 1977, 132, 235-246.	1.1	137
1001	Areal and laminar distribution of some pulvinar cortical efferents in rhesus monkey. <i>Journal of Comparative Neurology</i> , 1976, 169, 371-391.	0.9	202
1002	A combined horseradish peroxidase-autoradiographic investigation of reciprocal connections between superior temporal gyrus and pulvinar in squirrel monkey. <i>Brain Research</i> , 1975, 85, 347-353.	1.1	73
1003	Amygdaloid projections to prefrontal granular cortex in rhesus monkey demonstrated with horseradish peroxidase. <i>Brain Research</i> , 1975, 100, 132-139.	1.1	88
1004	Corticothalamic neurons and thalamocortical terminal fields: An investigation in rat using horseradish peroxidase and autoradiography. <i>Brain Research</i> , 1975, 85, 385-401.	1.1	121
1005	Peroxidase labeled subcortical afferents to pulvinar in rhesus monkey. <i>Brain Research</i> , 1975, 97, 144-150.	1.1	63
1006	The cells of origin of the corpus callosum in rat, cat and rhesus monkey. <i>Brain Research</i> , 1974, 74, 149-155.	1.1	266
1007	Medial pulvinar afferents to frontal eye fields in rhesus monkey demonstrated by horseradish peroxidase. <i>Brain Research</i> , 1974, 80, 395-411.	1.1	93